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Statement of Problem: Infants undergoing intestinal surgery are at risk for feeding intolerance 
and resultant complications, including intestinal failure and intestinal failure-associated liver 
disease (IFALD). In infants, IFALD is defined as a persistent direct bilirubin (DB) >2mg/dl for 
>1 week in the setting of parenteral nutrition (PN) and can lead to liver failure. The optimal 
strategy for feeding post-operative infants to reduce PN exposure is poorly understood. We 
hypothesized that a more systematic approach to providing enteral nutrition (EN) would reduce 
the risk of IFALD. 
Methods: We conducted three studies: 1) A retrospective descriptive analysis of the baseline 
feeding practices and incidence of IFALD among surgical infants in the Neonatal Intensive Care 
Unit, 2) An interval analysis (pre- and post-intervention) 15 months after implementation of 
newly devised feeding guidelines using run-charts to measure adherence to feeding 
recommendations and peak direct bilirubin in real-time, and 3) A final analysis 2.5 years after 
guideline implementation to measure the overall impact of the feeding guidelines on IFALD 
incidence and severity using logistic regression.  
Results: We identified variable feeding practices and a high baseline incidence of IFALD, 66% 
(confidence interval [CI] 0.55 - 0.76) among all surgical infants and 90% (CI 0.78 – 1.01) among 
those needing >60 days of PN from 2007-2012. In the 15-month post-guideline analysis, a shift to 
reduced time to reach feeding goals (initiation and 50% EN) and decreased peak DB were seen on 
run-charts. In the final analysis, the initial post-operative EN median volume increased from 10 to 
20 ml/kg/day (P=0.001). Time to reach 50% EN decreased from a median of 10 to 5 days 
(P=0.013). The overall incidence of IFALD improved from 71 to 53% in infants needing >7 days 
of PN (P=0.03), and the median peak DB decreased from 5.7 to 2.3 mg/dl (P=0.003). The 
adjusted odds for developing moderate-severe IFALD were reduced by 67% in the post-guideline 
cohort, compared to the pre-guideline baseline (P=0.002). 
 iii 
Conclusions: The feeding intervention was well tolerated and resulted in shorter time to initiate 
EN and reach 50% of goal EN post-operatively. The incidence and severity of IFALD also 
improved.  
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CHAPTER 1: INTRODUCTION 
The Impact of Intestinal Surgery in Infants 
 Infants requiring intestinal surgery are at risk of multiple complications, including severe 
malabsorption and dysmotility that results in intestinal failure (IF).  IF is the inability of the 
intestine to absorb sufficient fluid, nutrients, and calories, and requires parenteral nutrition (PN) 
to meet metabolic demands and sustain growth. Dependence on parenteral nutrition (PN) for at 
least 30-60 days is needed to meet the definition of IF. IF occurs in up to 24 per 100,000 live 
births and is associated with high rates of morbidity and mortality.1,2 IF patients have prolonged 
hospitalizations, with estimated costs over $500,000 in the first year of life and approaching $1.6 
million by five years of age.3  Children requiring home PN have more frequent ambulatory visits, 
hospital admissions, and total care costs compared to those not requiring PN.4 Children with IF 
are also at risk for neurodevelopmental delay.5 
 The most common etiology of IF in infants is surgical intestinal resection (short bowel 
syndrome), and the most common reason for intestinal resection is necrotizing enterocolitis 
(NEC), which can result in massive intestinal necrosis. Despite numerous advances in neonatal 
intensive care, NEC continues to affect 7% of preterm infants and remains a highly morbid 
condition.6,7 Other etiologies of IF in the infant population are spontaneous intestinal perforation 
(SIP), gastroschisis, intestinal atresia, volvulus, omphalocele, and Hirschsprung’s disease.  
 One of the most common complications of IF is intestinal failure-associated liver disease 
(IFALD). As IFALD manifests as cholestasis in infants, a general definition is persistent direct 
bilirubin >2mg/dl for > 1 week in the setting of PN use and absence of other liver disease.8,9 The 
terminology has changed over the years to better reflect the multi-factorial process associated 
with IFALD, and it has previously been known as PN-associated cholestasis (PNAC) and PN-
associated liver disease (PNALD). Cholestasis can occur in less than 14 days of PN exposure.10 
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IFALD is common, occurring in 25-60% of surgical infants, but occurs in up to 80% of infants 
with necrotizing enterocolitis (NEC).10-13  
 IFALD is a significant burden for surgical infants. Chronic liver disease may develop in 
up to two-thirds of neonates with IF.11 Liver failure develops in 25-40% of patients with IF after 
bowel resection, who ultimately require liver or liver/bowel transplantation.14 Over 900 pediatric 
patients were listed for combined liver and bowel transplantation from 1987-2004.15 The 
mortality of IFALD alone can be 10-15% in the non-transplanted population.2,16 In the immediate 
post-operative period, anticipating which infants will develop IFALD is difficult. Furthermore, 
even if serum bilirubin and transaminases normalize after IFALD, liver fibrosis may continue to 
progress to cirrhosis, especially in infants still requiring PN.17,18 It is therefore prudent to reduce 
IFALD risk in all surgical infants. 
The Etiology of IFALD 
 IFALD is a multifactorial process most impacted by 1) chronic exposure to the 
hepatotoxic effects of PN, 2) insufficient EN, which alters gut barrier function and disrupts 
immune function, and 3) systemic inflammation, including infection (Figure 1).11,19-22 Currently, 
the only intravenous lipid preparation approved by the Federal Drug Administration is a soy-
derived preparation rich in linoleic acid, a fatty acid that is readily metabolized along the 
arachidonic pathway into pro-inflammatory eicosanoids. Soy based lipids also contain 
phytosterols which have been shown to have direct toxic effects on the liver. These plant sterols 
accumulate in the liver of patients with intestinal failure and are correlated with liver injury.23  
Limiting the dose and frequency of exposure soy lipids has reversed IFALD in some cases.24,25 
Complete removal of lipids from PN is imprudent, as essential fatty acids are crucial for growth 
and development. Other surgical factors that contribute to risk of IFALD include absence of an 
ileocecal valve and the length of remaining bowel.26   
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 Prematurity and low birth weight are both risk factors for IFALD.27,28 These infants 
typically receive PN within the first 1-2 days of life to prevent growth failure. They are also 
susceptible to multiple feeding interruptions requiring ongoing PN supplementation, so the 
cumulative exposure to PN is greater than term infants.29 The immature livers of preterm infants 
are less able to process the toxic components of PN, and the enterohepatic bile circulation may 
not be fully developed.28,30 Given their lengthier hospitalizations compared to term infants, 
preterm infants are at greater risk for infection, especially catheter related blood stream 
infections.31 Preterm infants are also at higher risk of developing NEC.  
The Benefits of Enteral Nutrition 
 Enteral nutrition (EN) is necessary for both preventing and reversing IFALD by 
maintaining a normal intestinal barrier function.32,33 When functioning normally, tight junctions 
between intestinal cells form a physical barrier that keep commensal bacteria, pathogens, ingested 
food, and other antigens within the intestinal lumen.34 The intestine has a direct role in immune 
modulation, and tolerance is regulated by “sensing” the microbial milieu and presenting antigens 
to innate and adaptive immune cells.35 Injury to the intestine disrupts the mucosal barrier, leading 
to inflammation, antigen permeability, microbiome alteration, and bacterial translocation, all of 
which increase immune activity.36 In animal models of bowel resection, radiolabeled bacteria and 
lipopolysaccharide (LPS), a pro-inflammatory gram-negative bacterial membrane product, are 
readily detected in the serum.37,38 LPS has also been detected in the serum after other forms of 
intestinal injury, including cholecystectomy and inflammatory bowel disease.39,40 Aberrant 
immune interactions with bacteria colonizing the intestine are implicated in the pathogenesis of 
NEC.7,41,42 Similarly, alterations in permeability likely exacerbate IFALD, as seen in other 
etiologies of chronic liver inflammation.43 The liver is perfused by blood leaving the GI tract 
through the portal vein- rich in nutrients but potentially laden with bacteria, antigens, and 
inflammatory cytokines. Intestinal injury and IFALD are therefore inter-related.  
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 The intestine requires direct stimulation from enteral nutrients to prevent mucosal 
atrophy, preserve tight junctions, and maintain appropriate immune interactions.44-47 In animal 
studies, intestinal atrophy occurs in a few days of withholding feeding; the timing is less clear in 
infants. EN is a substrate for the commensal microbiota and can influence which organism 
populations thrive.48 EN induces the brush border disaccharidases (i.e. lactase, isomaltase) 
necessary for carbohydrate digestion and absorption.49 EN also stimulates trophic hormones that 
regulate bowel and biliary function - cholecystokinin, glucagon, motillin, and secretin.50 These 
hormones are critical for adaptation, the process where the residual gut hypertrophies and takes 
on the role of absorbing specific nutrients previously performed by the resected bowel.44,51,52 
Breast milk is particularly beneficial in helping the bowel adapt, providing immunoglobulins, 
glutamine, and hormonal and other growth factors.53,54 If breast milk is not available or not 
tolerated, a common substitution is an elemental (amino acid based) formula.55-57 These formulas 
also have a higher concentration of medium-chain fatty acids, which can be directly absorbed by 
the enterocytes, and do not require a functioning enterohepatic pathway for lipid metabolism. The 
sooner EN begins, the sooner adaptation begins. 
 Despite the known importance of starting EN “as soon as possible” to induce adaption 
and prevent IFALD, best-practice guidelines are lacking.32,57,58 Significant variability therefore 
exists in post-surgical nutrition practices for infants. The optimal timing of EN after injury, 
delivery (bolus vs. continuous), and rate of advancement are poorly understood and are provider-
dependent.55 The Pediatric Intestinal Failure Consortium, consisting of 14 sites with specialized 
care for infants with IF performed a retrospective review of children less than 12 months of age 
who had received at least two months of PN due to IF.59 Twenty-two different formulas were 
used and only 19% of infants received breast milk.  The investigators reported a wide range of 
feeding practices within and between sites, and highlighted the need for multi-centered trials to 
investigate feeding practices for children with IF.  
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Barriers to Enteral Feeding  
 While it is recognized that enteral feedings are important, barriers do exist to using 
enteral feeds in neonates after surgery. Historically, patients are not fed after bowel surgery for 
several days until bowel function returns (passage of flatus or stool), though this notion has 
recently been challenged in both the adult and pediatric literature, and earlier feedings (sometimes 
within 24 hours) have been proven safe.60,61 The same studies have not been done in the more 
fragile neonatal population, but they do suggest that a prolonged waiting period to begin feeding 
may not be necessary. Following necrotizing enterocolitis (NEC), the most common cause for 
bowel resection, feeding is withheld as part of treatment. Traditionally, neonates are not fed for 7-
14 days, sometimes longer if the infant remains critically ill. Two small studies have recently 
shown that earlier feedings, beginning 5 days post-NEC in one group and a mean of 8 days post-
NEC in the other, resulted in fewer complications, including recurrence of NEC and catheter-
related sepsis episodes.62,63 However, given the high mortality rate and risk of recurrence, many 
providers are apprehensive about feeding after NEC.  
Utility of Feeding Protocols in Neonatal Settings 
 Feeding guidelines are emerging in an effort to balance the benefits of EN with the risk of 
NEC in high-risk infant populations.29,64 Early feeding likely has advantages. A study of 
premature infants showed early feeding (within 48 hours of birth) improved feeding tolerance and 
decreased exposure to PN, without an increase in NEC.65 Recent studies evaluating feeding 
protocols in surgical infants show that early feeding actually improves motility and decreases 
exposure to PN, without an increase in complications.55 To begin EN, many centers have 
implemented minimal EN (trophic feeding) regimens as a strategy to stimulate intestinal mucosa 
without providing significant calories, thought to reduce the occurrence of feeding intolerance 
and NEC; however, broad ranges in volume from 5-25 ml/kg/day make these studies difficult to 
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compare and determine the ideal volume and duration of minimal EN.66 A Cochrane review 
found no difference in advancing EN by 15-20 ml/kg/day vs. 30-35 ml/kg/day in preterm infants, 
but had limited data on extremely preterm infants.67 Feeding protocols have also been 
implemented in other populations at higher risk for NEC, including infants with very-low-birth-
weight and congenital heart disease, which have resulted in both faster and safer achievement of 
feeding goals, without increased risk of intestinal perforation due to NEC.62,63,68 The American 
Society for Parenteral & Enteral Nutrition (ASPEN) found sufficient evidence to support early 
initiation of EN and advancing by 30 ml/kg/day in non-surgical infants at-risk for NEC, but initial 
volume is not specifically mentioned.69 They did not find sufficient evidence to recommend 
timing of EN following NEC. While questions about EN for surgical infants remain, a recent 
systematic review reported improved outcomes in general among surgical infants cared for by 
multi-disciplinary Intestinal Rehabilitation teams focused on nutrition support.70  
 How best to feed infants after bowel injury or resection is an unanswered question, and is 
of significant importance for preventing IFALD. Given the potential for progressive liver disease 
and its associated mortality, primary prevention is preferable to treatment. Earlier, systematic 
introduction of enteral feeding has potential to improve gut function and adaptation, including 
systemic immune regulation, thereby reducing IFALD risk. The following chapters describe the 
baseline incidence if IFALD and post-operative feeding practices at our institution, the 
development and implementation of a post-operative feeding protocol, including our 






Figure 1. Conceptual Framework of Factors in IFALD Development 
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CHAPTER 2. ANALYSIS OF NUTRITION PRACTICES AND INTESTINAL 




Introduction: The incidence of intestinal failure-associated liver disease (IFALD) varies 
following intestinal surgical intervention in infants, ranging from 25-60%. While IFALD  
resolves in some infants, 40% of infants who require long-term parenteral nutrition (PN) progress 
to liver failure. The purpose of this study was to investigate the incidence of IFALD at our center 
among infants requiring intestinal procedures and to assess post-operative feeding practices. 
Methods: We performed a retrospective review of infants with intestinal surgical procedures 
before six months of age from 2007-2012. Infants with pre-existing liver disease, other than 
IFALD, were excluded. The primary outcome was incidence of IFALD during the initial 
hospitalization. Timing of IFALD development and median time to reach enteral nutrition goals 
were investigated. 
Results: Of the 82 surgical infants, the overall incidence of IFALD was 66% (confidence interval 
[CI] 0.55 - 0.76), and among the 30 infants requiring >60 days of PN, the incidence was 90% (CI 
0.78 – 1.01). Median direct bilirubin of those with IFALD was 7.5 mg/dl. Infants with IFALD 
were more likely to be premature (29 vs. 38 weeks, P<0.001), have necrotizing enterocolitis (54% 
vs. 17%, P=0.002), and have culture-positive infection (42% vs. 7%, P=0.001). Among the most 
recent 24 infants, median time to introduce enteral nutrition post-operatively was 17 days 
(interquartile range [IQR] 9-26), and median time to reach 50% of calories from enteral nutrition 
was 34 days (IQR 23-50). 
Conclusions: The risk of IFALD is common at our center. Multi-disciplinary preventive and 
therapeutic strategies need to be investigated.  Future investigation will focus on the time to reach 




 Infants who require intestinal procedures, such as bowel resection, are at risk for 
developing intestinal failure-associated liver disease (IFALD). IFALD is poorly defined, but a 
commonly used definition for infants is persistent cholestasis (serum direct bilirubin >2mg/dl for 
at least 7 days) in the setting of parenteral nutrition (PN) use and in the absence of other primary 
liver disease.8,9 While IFALD may be perceived as a temporary, even anticipated, side effect, it 
can be detrimental in infants who require prolonged (>60 days) PN.  In this population, IFALD 
frequently persists and becomes a significant predictor for chronic liver disease and 
death.2,11,14,59,72 End-stage liver disease develops in up to 40% of such patients, necessitating liver 
and/or small bowel transplant.14 
IFALD reportedly occurs in 25-60% of infants undergoing bowel resection.10-12 
Following resection, it may not be known for several weeks which infants will eventually tolerate 
enteral nutrition (EN). By that time, significant liver damage may have occurred. Though serum 
markers of liver injury may return to normal and liver biopsies improve as IFALD resolves, 
fibrosis of the liver can persist.17,18,73,74 If progressive, hepatic fibrosis ultimately leads to cirrhosis 
and liver failure. Furthermore, it remains unknown if infants who’ve had normalization of liver 
tests after IFALD will be more susceptible to other hepatic insults as they age, such as viruses and 
alcohol.  Preventing, or at least decreasing, the severity of IFALD in all infants is therefore 
prudent. 
 Preterm infants are at greater risk for developing IFALD after intestinal procedures.27,28 
Preterm infants have multiple interruptions in feeding, resulting in a higher cumulative exposure 
to PN. Their premature livers may also be more susceptible to the accumulation of phytosterols 
found in the lipid component of standard soy-based PN.30,75,76 Additional factors such as poor in 
utero growth can further impair liver function.77 Prolonged lack of feeding can disrupt the gut 
barrier, altering immune function and increasing risk of infection.44,50 Though EN is important for 
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preventing IFALD, post-surgical feeding practices are not well described in the literature. In fact, 
very little evidence exists to guide providers as to the appropriate time to initiate and advance EN 
post-operatively.58 
 As part of a quality improvement initiative to coordinate multispecialty care for infants 
undergoing intestinal procedures, we performed a retrospective cohort study to determine the risk 
of IFALD at our institution. The purpose of this study was to perform a critical analysis of the 
risk factors for IFALD in our population, including enteral feeding practices, to provide a rational 
basis for future strategies to decrease IFALD risk in infants who require intestinal surgical 
intervention.  
METHODS 
Study Design and Population 
We performed a retrospective cohort study using billing codes for abdominal surgical 
procedures in the neonatal intensive care unit (NICU) from January 2007 to December 2012 after 
approval from the Institutional Review Board. Intestinal resection was the primary surgical 
procedure included; however, stoma creation and peritoneal drain placement for intestinal 
perforation were also included in the absence of bowel resection for appropriate diagnoses. 
Patients were included if the surgical intervention occurred before six months of age and PN was 
received post-operatively. Patients were excluded for pre-existing liver disease, other than 
IFALD. In the case of multiple procedures or admissions, data pertained to the hospitalization in 
which the first intestinal procedure occurred. Data were collected over the course of the entire 
hospitalization, which could include transfer to an acute care unit. Due to a change in electronic 
medical record format, specific feeding data were only available for the most recent 24 patients 
who had procedures from July 2010 to December 2012. 
Assessment of Risk Factors and Outcomes 
 11 
For all patients, we recorded race/ethnicity, sex, gestational age, gastrointestinal 
diagnosis, age at time of surgery, length and location of resection, positive blood/urine/peritoneal 
cultures, peak and final direct bilirubin by time of hospital discharge, cumulative days of PN 
before and after surgery, dependence on PN at hospital discharge, development of necrotizing 
enterocolitis (NEC) after resuming EN, mortality and cause of death. Length of bowel resection 
was obtained from the operative and/or surgical pathology report. Residual small bowel length 
was taken from the operative report when available. Liver function tests were measured 1-2 times 
per week, with more frequent measurements as indicated for changing clinical status.  
The PN formulation was written daily by the primary neonatology service with 
recommendations from registered dieticians. The total volume varied by gestational age, and 
ranged from 80-120 ml/kg/day. Soy-based lipid emulsions were typically advanced to 3 g/kg/day. 
Lipid-sparing strategies were implemented on an individual basis once direct bilirubin reached 
2mg/dl. If growth was acceptable, the goal was a reduction of lipid to 1-1.5 g/kg/day, along with 
cycling of trace elements (copper and manganese) three times weekly. Zinc and selenium were 
still given daily, as was chromium when available. Intravenous fish oil lipid emulsion was not 
available for use. 
The decision of when to initiate EN post-operatively, the starting volume, route, and 
criteria for advancing feeding was NICU provider dependent with input from the surgical service. 
Initial feeding volumes and rate of advancement were dependent on the underlying condition in 
addition to the gestational and chronologic age of the infant. Caloric requirements were 
determined by registered dieticians based on post-natal age and growth parameters. However, 
there was not an integrated intestinal rehabilitation service.  
The primary outcome was cumulative incidence, or risk, of IFALD. IFALD was defined 
as cholestasis attributed to PN, with serum direct bilirubin of ≥2.0 mg/dl on two occasions at least 
one week apart, in the absence of other known liver disease. Onset of IFALD was defined as the 
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first date where direct bilirubin was ≥2.0 mg/dl.  We defined severe IFALD as a direct bilirubin 
>10mg/dl, based upon previously reported severity levels that predict worse outcomes.2,78 
Feeding outcomes included the number of post-procedure days to initiate EN, days to reach 50% 
of goal calories from EN (50-60kcal/kg/day), and days to reach 100% of goal calories from EN 
(>100kcal/kg/day with cessation of PN).   
Statistical Analysis 
 Fischer’s exact test was used to determine differences in categorical characteristics 
between the infants who developed IFALD and those who did not. Non-parametric Wilcoxon 
rank-sum tests were used to compare the medians of continuous variables between the groups. 
Student t-tests were used to compare the means of continuous variables. A two-sided p-value of 
<0.05 was considered statistically significant. The Nelson-Aelen cumulative hazard estimates of 
the rate of IFALD after the start of PN were generated and plotted. Most infants received 
continuous PN through the peri-operative period. We explored calendar days from the time of PN 
start and actual days of PN. There was no difference between the two. We investigated this 
outcome and all the potential risk factors through a multivariate Cox proportional hazard 
regression model. The risk factors considered were sex, race (White versus other), prematurity 
(gestational age <28 weeks, 28-35 weeks, and >35 weeks), age at surgery, etiology (NEC versus 
other), culture positivity for any infection, and presence of ileocecal valve. The final model 
included sex, race, etiology, and prematurity as those were the most clinically and statistically 
relevant variables. STATA (StataCorp. 2011. Stata Statistical Software: Release 12. College 
Station, TX: StataCorp LP) was used to perform all statistical analyses. 
RESULTS 
From the 2007-2012 billing data, 83 infants met inclusion criteria. One infant was 
excluded for a diagnosis of biliary atresia, leaving a total of 82 infants. Given the lag in billing 
data, 8 patients had their initial procedure in 2006 but were billed in 2007. Seventy-one infants 
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had bowel resection (26 had a primary anastomosis and 45 had stomas). Eleven infants had 
stomas without resection.  
The clinical characteristics of those infants with and without IFALD are displayed in 
Table 1. Infants who developed IFALD were more likely to be premature (P<0.001), have NEC 
(P=0.002), have culture-positive infections (P=0.001), and have longer PN requirements 
(P<0.001). Infants who did not develop IFALD were more likely to have Hirschsprung’s disease 
or simple intestinal atresia. Of the 71 infants with resection, resection length was available for 51 
infants. There was no difference in length of documented intestinal resection between the groups; 
however more infants with IFALD had a residual small bowel length less than 50 cm.  Eight 
infants with short bowel syndrome had residual bowel measured, ranging from 12 – 39 cm. Only 
one such infant did not develop IFALD (residual small bowel 20 cm). The location of bowel 
injury was 50% ileum, 19% jejunum, 18% multiple small bowel locations, 7% colon, and 6% 
duodenum.  
The overall incidence of IFALD was 66% (95% Confidence Interval [CI] 0.55 - 0.76). 
The cumulative hazard for developing IFALD after initiation of PN is displayed in Figure 2. The 
rate of IFALD began to rise steeply after 10 days of PN. Of the 49 infants requiring at least 30 
days of PN, 47% (95% CI 0.31- 0.61) had developed IFALD by 30 days. By 60 days of PN, 27 of 
30, 90% (CI 0.78 – 1.01), had developed IFALD. Thirteen infants (25%) had IFALD prior to 
surgery. Sixteen infants (20% of the total cohort) required PN at hospital discharge, 88% of who 
had IFALD (CI 0.69 – 1.06).  
The final Cox regression model included sex, race, etiology, and prematurity. Prematurity 
remained the only significant risk factor, with extremely premature infants (gestational age <28 
weeks) having an increased hazard of developing IFALD compared to term infants (gestational 
age >35 weeks), hazard ratio=3.2 (CI 1.05-9.9, P=0.04). 
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The degree of cholestasis varied by diagnosis, which was related to the overall length of 
PN exposure. Infants with gastroschisis had the highest median peak direct bilirubin, followed by 
infants with NEC (Figure 3). Among infants with IFALD, 26% (14/54, CI 0.14-0.38) developed 
severe cholestasis with a direct bilirubin >10mg/dl. Eight infants (15%, CI 0.05-0.25) had 
resolution of IFALD by discharge, with a direct bilirubin <2 mg/dl. Five patients (9%, CI 0.01-
0.17) eventually developed chronic liver disease (defined as coagulopathy with abnormal liver 
enzymes or evidence of liver fibrosis/cirrhosis). 
Mortality during the first hospitalization was similar among those infants with and 
without IFALD (6% vs. 7%, P=0.56). Of the five infants who died, four had NEC and one had 
volvulus with necrosis of the entire bowel. Among those with NEC, one died in the first 24 hours 
of life due to ischemic bowel/peritonitis, one died of a massive pulmonary hemorrhage shortly 
after bowel resection, and two died of respiratory failure several weeks after bowel resection.  
Four patients developed NEC post-operatively after EN was started (7%, CI 0.02-0.17).  
The clinical characteristics of the most recent 24 infants with EN data were similar to 
those of the entire group. The most common diagnosis was NEC (54%), and the mean gestational 
age was 29.8 weeks (IQR 25.3 – 34.1). All infants required at least 14 days of PN, with a mean of 
71 days (IQR 48-112). One third of the infants were discharged with home PN. 
 The time to reach specific EN goals in the 24 infants is displayed in Table 2. Twenty-two 
infants started on trophic feeding, generally between 5-10 ml/kg/day, though the range was 2-14 
ml/kg/day. Fifteen infants received breast milk, one infant received cow’s milk formula, two 
infants received partial hydrolysate formula, and six infants received elemental formula. Bolus 
feeding was started in 67% of the infants, and the others received continuous feeding. Not all 
patients reached 50% or 100% of goal calories from EN by the time of hospital discharge. When 
comparing all etiologies of bowel resection, only 38% of the infants achieved 50% of goal 
calories from EN within 30 days of surgery.  All but three infants (88%) developed IFALD. Six 
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infants (25%) had IFALD by the time of surgery, 13 infants (54%) developed IFALD within 30 
days of surgery, and two infants (8%) developed IFALD after 30 days. The median peak direct 
bilirubin was 6.9 mg/dl (IQR 5.3-12).  
 Among the 24 patients, lipid reduction was employed once direct bilirubin was above 
2mg/dl. At the time of meeting criteria for IFALD, 4 infants were already on 1g/kg/day of lipid, 
and 2 infants were off of lipid completely. The lipid dose was lowered from 2-3 g/kg/day to 1-
1.5g/kg/day within 24 hours for 6 infants and within 3-4 days for another 4 infants. Five infants 
had their lipid dose lowered from 3g/kg/day to 2g/kg/day within 24 hours, but the dose was not 
lowered further until 10-27 days after meeting criteria. Three infants never developed IFALD 
despite receiving 3 g/kg/day of lipid for a minimum of 14-30 days after their procedure.  
 Serum direct bilirubin, which is required for the diagnosis of IFALD, was not always 
routinely monitored in the post-operative period, though other liver tests including total bilirubin 
were measured at least 1-2 times per week. Direct bilirubin is not always measured if the total 
bilirubin remains below 2 mg/dl. Fourteen of the infants without IFALD did not have a post-
operative direct bilirubin level. Nine of these infants had relatively short hospitalizations and 
were not clinically jaundiced so IFALD was not suspected. Five infants did have elevated total 
bilirubin levels, so may have been misclassified as not having IFALD. Many of the IFALD 
infants did not have a direct bilirubin measured for 2-4 weeks post-operatively, and the first 
available date was used. 
DISCUSSION   
Historically, the incidence of IFALD among surgical infants ranged from 40-60%, but the 
incidence varied by center and patient population.10-12 A recent systematic review reported an 
overall incidence of 30% among all infants (including preterm) and children with at least 14 days 
PN exposure, and 50% incidence among infants with intestinal failure.12 While not included in 
the systematic review, one center with an active intestinal rehabilitation program reported an even 
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lower incidence of 25% among surgical infants.10  Compared to other centers, our incidence of 
66% was at the higher end of the spectrum. Among infants with prolonged PN exposure for >60 
days, our incidence was 90%. This incidence was again higher, but along the same trend of the 
75% risk recently published by the National Intestinal Failure Consortium which evaluated a 
cohort of 272 infants from 14 sites with at least 60 days of PN exposure.59 Early prognostic 
factors for IFALD include low birth weight (<750 g), and etiology of intestinal disease, with 
gastroschisis, jejunal atresia, and NEC portending higher risk.13,79 The risk of IFALD among 
surgical NEC patients ranges from 56-85%.13 The most common diagnoses among our infants 
with IFALD were NEC, atresia, and gastroschisis. Our higher risk may be related to a case mix of 
higher acuity infants, other etiologies being attributed to IFALD (sepsis or multi-organ system 
failure), or chance, given the relatively small cohort. Another important consideration is that 
feeding practices contributed to IFALD, given the time to initiate and advance EN.  
 Early advancement of EN has been associated with preventing and resolving IFALD;32,33 
however, reaching feeding goals can be difficult for multiple reasons. Infants may have 
significant feeding intolerance related to the location and size of resection, dysfunction of the 
residual bowel, and may have other severe organ dysfunction necessitating interruption of EN. 
Furthermore, providers may be hesitant about aggressive feeding for fear of causing another 
episode of NEC. The ideal composition of EN that is best tolerated and able to stimulate bowel 
adaptation is also unclear.  Breast milk is an appealing option given the nutritional and immune 
benefits, as well as reduced risk of NEC.80 The use of breast milk and amino acid formulas has 
been associated with less PN use, which may impact the development of IFALD, but this has not 
been conclusively demonstrated.81 Providers have limited evidence to guide them in initiating and 
advancing EN after intestinal injury, leading to practice variability.58 
 The majority (54%) of our patients with IFALD had bowel resection due to NEC. The 
median time to initiate EN after resection in infants with NEC was 21 days, and the median time 
 17 
to reach 50% of goal EN was 47 days, though some cases were significantly longer. Infants with 
NEC requiring surgical resection often have concomitant multi-organ dysfunction which may 
contribute to delayed initiation of EN. When comparing all etiologies of bowel resection, nine of 
the 24 infants (38%) achieved 50% of goal EN within 30 days of surgery. Again the delay in 
advancing EN may be a reflection of overall severity of illness and feeding intolerance; however, 
another contributing factor may be low starting volumes of trophic feeding and slow 
advancement regardless of tolerance. Over half of our infants (60%) received breast milk post-
operatively, but the volume and timing may not have been sufficient to offer protection against 
IFALD. 
Once IFALD occurs, it can be difficult to resolve if EN is not advanced so that PN can be 
weaned. Many of our infants (65%) had an improved direct bilirubin (decrease of at least 1 
mg/dl), but only 19% had resolved IFALD by discharge from the hospital. Among the 14 infants 
with IFALD who were discharged home with PN, 78% still had a direct bilirubin >2 mg/dl. In 
this setting of intestinal failure and prolonged PN exposure, IFALD becomes a significant 
predictor of mortality and need for transplantation.2,14  
Other treatment options for IFALD are few. Ursodeoxycholic acid, which improves bile 
flow, has been used with limited success.82 Glutamine, a preferred fuel for enterocytes, has shown 
promise in animal studies by stimulating mucosal growth and barrier function, but has yet to be 
proven beneficial in human infant studies.83 Another common practice is to reduce the dose of 
soy-based lipid once cholestasis occurs.24,27  
In our population, those infants not already receiving ≤1 g/kg/day had at least some 
reduction in lipid dose, but lipids were given daily. It is unclear if the timing or degree of lipid 
reduction, such as limiting lipids to 2-3 days per week, may have impacted the degree of 
cholestasis.  Although retrospective, a recent publication by Nehra et al, showed no difference in 
the development of IFALD when infants only received 1 g/kg/day of soy-based lipid versus the 
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standard 2-3 g/kg/day.84 A study by Levit also found no difference in incidence of cholestasis 
among preterm infants given 1g/kg/day vs. standard doses of soy lipid in first two weeks of life; 
however, their definition of cholestasis included many infants with a direct bilirubin <1mg/dl and 
few infants required intestinal surgery.85 These findings call into question the utility of this 
practice, though further lipid restriction may offer more benefit. Cober et al did show an 
improvement in total bilirubin level over time when infants with IFALD were treated with severe 
lipid restriction to 1g/kg/day given twice weekly compared to historical controls given standard 
doses. This practice was also associated with mild essential fatty deficiency, so careful 
monitoring is warranted.86 
Alternative lipid preparations containing omega-3 fatty acids are widely used across 
Europe to treat IFALD in infants and show promising results for reversing IFALD.78,87 
Unfortunately, these preparations are not yet approved by the Federal Drug Administration in the 
Unites States. While these emulsions can be obtained for compassionate use after the onset of 
IFALD as an investigational new drug, the cost is prohibitive to many institutions and individual 
families. Furthermore, even if cholestasis improves with fish oil lipid emulsion, liver fibrosis may 
not always be reversible, and may still ultimately progress to liver failure.17,73,74  
Multi-disciplinary strategies for advancing EN, PN manipulation, and infection control 
aimed at primary prevention of IFALD may be of benefit.  Earlier introduction of EN with careful 
but consistent advancement may reduce the burden of IFALD by 1) enhancing gut barrier 
function and motility, thereby reducing bacterial translocation and subsequent infection,21,44,50 2) 
attenuating gut-immune system interactions that influence pro-inflammatory responses,88 and 3) 
reducing exposure to hepato-toxic PN components.  Feeding protocols have been successfully 
implemented in other high-risk infant populations, including very-low birth weight infants and 
those with hypoplastic left heart syndrome.68,89-91 While both groups have an increased risk of 
NEC at baseline, infants who followed a feeding protocol had better growth with either the same 
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or decreased incidence of NEC, compared to controls. In adults, it is now standard practice to 
introduce EN within 24-48 hours after uncomplicated bowel resection, rather than the traditional 
practice of waiting several days for bowel function to return.61 Small studies have begun to look 
at earlier introduction of feedings in pediatric post-operative populations, with promising results 
regarding tolerance and length of hospitalization.60 Of course, infants with complicated bowel 
resection, such perforation from NEC, will likely need different guidelines than those with simple 
resection, due to potential injury in the residual intestine. 
Our study has several limitations. This is a single-center retrospective study with a 
relatively small population. Direct bilirubin levels were not monitored in a systematic fashion 
post-operatively and length of bowel resection or residual bowel was not readily identifiable for 
all patients. Details regarding enteral feeding were only available for the most recent 24 patients. 
Due to the sample size and heterogeneous population, we could not create a risk score for 
developing IFALD, which would ultimately require a multi-center database to capture sufficient 
patients. The analysis only reflects short-term outcomes that occur within the initial 
hospitalization. 
In conclusion, IFALD is common at our institution, occurring in about two-thirds of 
infants requiring intestinal procedures, and in 90% of infants with prolonged PN requirements. 
While many factors contribute to IFALD, the timing and volume of EN post-operatively may be 
important and modifiable in many infants. Being aware of high-risk infants should prompt careful 
monitoring of liver function, attention to enteral and parenteral nutrition prior to the development 
of IFALD, and meticulous line care to prevent infection. Our findings have motivated us to form 
a multi-specialty intestinal rehabilitation team to address these issues. Our future plans include 













Sex   Male (%) 39 (72) 18 (64) 0.310 
Race/Ethnicity (%)   0.015 
Black (non-Hispanic) 23 (43) 8 (28)  
White (non-Hispanic) 26 (48) 11 (39)  
Hispanic 0 (0) 5 (18)  
Asian 1 (2) 1 (4)  
Other 4 (7) 3 (11)  







Diagnosis (%)   0.002 
NEC 29 (54) 5 (17)  
SIP 4  (7) 2 (7)  
Atresia 7  (13) 10 (36)  
Volvulus 4  (7) 1 (4)  
Gastroschisis 6  (11) 1 (4)  
Hirschsprung’s 3  (6) 6 (21)  
Meconium ileus 0  (0) 2 (7)  
Other 1  (2) 1 (4)  
Age at surgery, days 
median (IQR) 
10 (3-28) 4 (2-11) 0.019 
Type of Procedure (%) 
Resection/anastomosis 
Resection/stoma 






















Ileocecal valve preserved, (%) 44 (86) 23 (88) 0.547 
PN pre-surgery, days 
median (IQR) 
8 (1-20) 1 (0-3) <0.001 
PN post-surgery, days 
median (IQR) 
46 (25-72) 7 (4-12) <0.001 
PN total, days 
median (IQR) 
60 (35-100) 9 (7-13) <0.001 
Positive blood culture, (%) 11 (20) 1 (4) 0.051 
Any positive culture, (%) 23 (42) 2 (7) 0.001 
Peak direct bilirubin, mg/dl 
median (IQR) 
7.5 (5-10) 0.5 (0.3-0.8) <0.001 
Discharge direct bilirubin, mg/dl 
median (IQR) 
3.9 (2.1-6.4) - - 
NEC after re-feeding (%) 4 (7) 0 (-) 0.181 
Deceased (%) 3 (6) 2 (7) 0.560 
IFALD= intestinal failure-associated liver disease; IQR=interquartile range; NEC=necrotizing enterocolitis; 
SIP=spontaneous intestinal perforation; mg/dl= milligrams per deciliter; PN= parenteral nutrition. 
*P value from Wilcoxon rank-sum test, student t-test, or Fischer exact test 




Table 2. Clinical and Nutritional Data for the 24 Most Recent Patients by Diagnosis, median (IQR)           
Diagnosis 
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(-) 30 -8 11.3 
IQR= interquartile range; Gest=gestational; EN=enteral nutrition; IFALD=intestinal failure-associated liver 
disease; PN=parenteral nutrition; NEC=necrotizing enterocolitis; SIP=spontaneous intestinal perforation; 
Volv=volvulus; Gastro=gastroschisis; Hirsch=Hirschsprung’s disease; CDH=congenital diaphragmatic 
hernia. 
Twenty-four patients initiated feeds.  Twenty-one patients achieved 50% enteral calories. Eighteen patients 
achieved 100% enteral calories. 21 of 24 infants developed IFALD (excludes 1 infant each with NEC, 







Figure 2. The cumulative hazard estimate of developing intestinal failure-associated liver disease 







Figure 3. Median Peak Direct Bilirubin by Diagnosis. Boxes represent the 25-75th interquartile 
range and bars represent the 10-90th percentile range. The line within the box is the median. Dots 
represent outliers above the 90th percentile. The reference bar is at 2mg/dl, the cut-off for 
cholestasis. Hirsch=Hirschsprung’s disease; Gastro=gastroschisis; Volv=volvulus; 












CHAPTER 3. IMPLEMENTATION OF FEEDING GUIDELINES IN INFANTS 
AT RISK OF INTESTINAL FAILURE92 
ABSTRACT  
Introduction: The objective was to implement feeding guidelines to reduce advancement time 
and the incidence of intestinal failure-associated liver disease (IFALD) among intestinal surgical 
infants requiring parenteral nutrition (PN).  
Methods: Feeding guidelines with higher initial enteral nutrition (EN) volume and specific 
advancement criteria were implemented for surgical infants <6 months old. Outcomes were 
compared between the pre- and post-guideline cohorts.  
Results: There were 57 pre-guideline and 33 post- guideline infants. The initial median EN 
volume improved from 10 to 20 ml/kg/day (P<0.001). Time to reach 50% of goal calories from 
EN decreased by a median of 6 days (P=0.012) without a change in NEC incidence after 
resuming feeding. IFALD incidence decreased from 70 to 48% (P=0.041), and median peak 
direct bilirubin (DB) decreased from 5.6 to 2.3 mg/dl (P=0.011).  
Conclusions: Feeding guideline implementation with higher initial feeding volume was well 
tolerated and resulted in faster achievement of 50% goal EN calories. IFALD incidence and peak 





 Infants who have undergone intestinal surgery often have feeding difficulty requiring 
parenteral nutrition (PN) and are at risk for intestinal failure (IF).57 IF is loosely defined as 
insufficient absorption necessitating prolonged PN, with PN use ranging from >30 to >60 
days.58,59 A common complication is intestinal failure-associated liver disease (IFALD), defined 
as cholestasis (direct bilirubin [DB] >2mg/dl) for a least one week in the setting of PN exposure 
and absence of primary liver disease.8 IFALD is a multi-factorial process related to lack of enteral 
nutrition (EN), high dose soy-based PN, and inflammation that can progress to liver failure.11,14,93 
Prematurity, low birth weight, necrotizing enterocolitis (NEC), and sepsis are risk factors for 
IFALD, often occurring simultaneously in this high-risk population.13,27 EN is critical for 
intestinal barrier function, helping prevent and reverse IFLAD.33 Lack of EN results in intestinal 
atrophy, translocation of bacteria, and intestinal permeability to dietary antigens, all of which 
promote systemic inflammation and exacerbate IFALD.57,88  
 We previously reported a IFALD incidence of 66% among all intestinal surgical infants 
at our institution with 90% incidence among infants needing >30 days of PN.71 Other centers 
report 25-60% incidence among similar infants.10,11,58 We discovered significant variability in 
trophic feeding practices following surgery, which may have contributed to our IFALD risk.  The 
initial EN volume ranged from 2-14 ml/kg/day, independent of gestational age or size, and 
consensus for advancing EN was lacking.  
 We hypothesized that adherence to a systematic approach to EN would reduce the time to 
reach goal EN compared to historical controls, and therefore would reduce overall PN exposure 
and the risk of IFALD. The specific aim of the project was to decrease the time to reach 50% of 
goal EN from a median of 11 days to <5 days, with the ultimate goal of reducing our overall 
incidence of IFALD from approximately 70% to <50% within two years. We anticipated that 
most infants would tolerate the lower volumes of EN with a noticeable reduction in time to reach 
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50% EN and greater variability in time to reach 100% EN, depending upon clinical factors and 
weight gain.  
METHODS  
 The study protocol was granted approval and waiver of consent by the Institutional 
Review Board as the study was determined to be “quality improvement.”  
 Setting. Our academic children’s center has a 45-bed neonatal intensive care unit (NICU). 
Annually, there are 750 NICU admissions with 15-30 intestinal surgical procedures. Neonatal 
dieticians round daily with the NICU teams, with daily consults from general surgery and as-
needed consults from gastroenterology. Prior to the intervention, we did not have formal 
intestinal rehabilitation (IR) team that convened in the immediate post-operative period.  
Planning and Study of the Intervention 
 Development of the Intestinal Rehabilitation Team and Feeding Guidelines. We formed a 
multi-disciplinary IR team, comprised of representatives from neonatology, pediatric surgery, 
pediatric gastroenterology, nutrition, pharmacy, and nursing, and we developed feeding 
guidelines for NICU infants requiring intestinal surgery. Feeding guidelines were based on 
evidence and consensus when evidence was lacking, and were in parallel with the existing NICU 
protocol for initial feeding of extremely low birth weight preterm infants (Figure 4).  
 Though questions about best practices remain, there is agreement that EN should be 
started as soon as possible in surgical infants.57 Earlier and higher initial volumes of minimal EN 
(trophic feeding), up to 20 ml/kg/day, have been demonstrated to be safe in other high-risk 
neonatal populations, including those with low birth weight, prematurity, and cyanotic heart 
disease.9,65,69 Breast milk is preferred in most situations, and may be beneficial for intestinal 
adaptation and further protection against NEC.69 Based on published data and clinical experience, 
we anticipated most infants would tolerate moderate volumes of EN.94 Our guidelines therefore 
recommended using the upper spectrum of minimal EN and advancing daily unless signs of 
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intolerance were encountered (Figure 4). Since implementing our guidelines, another review 
reported similar recommendations to ours for monitoring tolerance by stool and ostomy output.95 
 The decision to use bolus or continuous EN was provider-dependent as evidence favoring 
a single feeding route is inconclusive;57 continuous EN was used if bolus EN was not tolerated. If 
breast milk was not available or declined, the type of formula was also provider-dependent; 
however, elemental formula was recommended in specific situations. Infants began oral feeding 
when developmentally appropriate.   
 Soy-based lipid was the only intravenous lipid available at our institution, and lipid 
restriction strategies did not change with the guidelines. PN goal calories were generally 100 
kcal/kg/day, based on age, growth and other needs. Lipid doses were typically advanced to 
3g/kg/day, unless cholestasis occurred. PN was weaned as absorption and weight gain allowed.  
 Implementation of Guidelines. Key drivers for implementation are displayed in Table 3.  
Initially, the IR team met monthly to discuss issues and modify the guidelines. Run charts were 
analyzed quarterly. After the first quarter analysis, we realized more immediate communication 
with the rounding teams was needed and weekly team rounds were implemented at five months 
with representatives from neonatology, nutrition, surgery, and gastroenterology.  
Methods of Evaluation  
 Study Design and Duration. This is a pre- and post-intervention study. Electronic medical 
records were available after 2010. Given the rarity of intestinal surgery, historical data was 
collected between January 2010 and June 2013, using billing codes to identify infants. Post-
guideline data were prospectively collected from infants admitted after October 14, 2013 who 
were discharged by February 28, 2015. As this was a quality improvement initiative, data was 
analyzed at 15 months (1 year following the first quarter ramp up period) to verify the utility and 
safety of guidelines.  
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 Study Population. Enrollment criteria included infants <6 months old with intestinal 
surgery at our institution at risk for IF based on diagnosis, procedure, and requirement of PN in 
the post-operative period. Target diagnoses were intestinal atresia, gastroschisis, omphalocele, 
volvulus, NEC, spontaneous intestinal perforation (SIP), or other primary intestinal conditions 
where >14 days of PN was expected. As the length of PN requirement is difficult to anticipate 
and we desired to capture all at-risk infants, infants with >7 days of post-operative PN were 
included. The target procedures were intraperitoneal drain, enterostomy or enterotomy with and 
without intestinal resection, and abdominal wall closure. Infants were excluded for primary 
surgical procedures performed at outside facilities or for liver disease other than IFALD.  
 Data Source and Metrics. Electronic medical records were reviewed by two trained 
analysts with periodic duplicate data review to ensure quality data extraction. Data were collected 
and managed using REDCap.96 Demographics, diagnoses, and surgical characteristics were 
recorded. Metrics were designed to be relevant, patient-centered outcomes, including process 
measures for adherence and balancing measures for safety. The primary outcome was IFALD 
incidence (DB >2mg/dl).  Other outcome metrics included IFALD severity (peak DB), discharge 
DB, days of PN, culture-positive infection (blood, urine, or peritoneal fluid), liver and/or 
intestinal transplantation evaluation, and length of stay. Process measures included days to initiate 
EN post-operatively, starting EN volume, days to reach 50% (>60 ml/kg/day with weaning PN) 
and 100% (>120 ml/kg/day and PN discontinued) of goal EN, and guideline adherence. 
Balancing measures included incidence of NEC (stage II or III) and mortality after post-operative 
feeding.  
 Data Analysis. Characteristics and outcomes between pre- and post-guideline cohorts 
were compared. Sub-analyses included evaluation of infants with NEC/ SIP diagnoses, preterm 
infants <34 and <28 weeks gestation, and exclusion of infants with <14 days of PN exposure. 
Given the small sample size and non-normal distribution of the data (determined by Shapiro-Wilk 
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test), non-parametric Wilcoxon rank-sum tests were used to compare the medians of continuous 
variables. Fisher exact tests were used to compare categorical variables. Statistical significance 
was set at a two-sided p-value of <0.05. Analyses were performed using STATA (StataCorp. 
2011. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP). 
 Individual data for specific outcomes were plotted in run-chart format to monitor 
performance over time. A “shift” was considered significant if 6 or more consecutive points were 
above or below the median as per Perla, et al.97  
RESULTS 
 Fifty-eight infants were identified in the pre-guideline cohort. One infant was excluded 
for pre-existing liver disease (biliary atresia); 57 infants were included. In the post-guideline 
cohort, 37 infants were identified. Two infants were excluded for other etiologies of liver disease 
(multi-organ failure and ischemic injury) and two infants with NEC died within 24 hours of 
surgery; therefore 33 infants were fed in the post-guideline period.  
 Baseline Characteristics. Baseline and surgical characteristics in the pre- and post-
guideline cohorts are presented in Table 4. There was not a statistical difference in gestational age 
or diagnosis between cohorts. The proportions of initial procedures were similar. Forty-four 
(77%) infants in the pre- and 20 (61%) infants in the post- guideline cohort had at least one 
resection, with more infants in the pre-guideline cohort requiring resection as a subsequent 
procedure (P=0.006). Most resections were relatively small and there was no difference in 
median total length of resection between cohorts. Residual bowel length was measured at the 
surgeon’s discretion and was only available for a few cases with large resections. Among 9 pre-
guideline infants, the median residual bowel was 30cm (28% of expected length based on 
gestational age), vs. 53 cm (34% of expected length), among 3 post-guideline infants (P=0.578). 
 Guideline Adherence. Nine infants had a total of 11 deviations from the guidelines, with 
all but two deviations occurring in the first four months of implementation, prior to weekly 
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rounds. Initial EN volume was lower than recommended for seven infants. Four infants had EN 
advancement that was slower than recommended. The deviations that occurred after 
implementation of weekly rounds were due to miscommunication. Previously unfed infants 
weighing <1000g who started at guideline-specific lower volumes were not considered 
deviations. 
 Changes in Feeding Practices. Nutrition metrics are displayed in Table 5. Most infants in 
both cohorts were fed breast milk initially. The initial volume increased from a median of 10 to 
20 ml/kg/day post-guideline implementation (P<0.001). The run chart shows a shift to higher 
feeding volumes (Figure 5) after introduction of weekly team rounds. The median time to initiate 
EN and to reach 50% of goal calories both decreased post-guidelines from 13 to 8 days (P=0.048) 
and 11 to 5 days (P=0.012), respectively. Run charts show a shift toward shorter time to reach 
50% EN (Figure 6) and 100% EN (Figure 7). In the subanalyses of preterm infants, improvement 
in time to reach 50% EN remained statistically significant (data not shown).  
 IFALD Incidence and Severity. IFALD incidence decreased from 70 to 48% (P=0.046) 
(Table 5), and the severity of cholestasis improved. The median peak DB decreased from 5.6 to 
2.3 mg/dl (P=0.011). The run chart shows a shift to lower peak DB among consecutive infants 
(Figure 8). As most infants received >14 days of PN, a sub-analysis of this group showed similar 
results. Infants with NEC or SIP had the highest peak DB, and a sub-analysis (N=30 pre- 
guideline and N=9 post-guideline) showed a median decrease in DB from 7.3 to 4.7 mg/dl 
(P=0.020). The significant reduction in peak DB was also seen in the subanalyses of preterm 
infants, but the proportion of IFALD was no longer statistically significant (data not shown). 
 Other Outcomes. Weight percentile by discharge was slightly better in the post-guideline 
cohort, with only 2 infants (6%) discharged below the corrected 10th percentile for age (z-score 
<2). The development of NEC after starting EN post-operatively was rare and similar between 
cohorts (Table 5). In the pre-guideline cohort, there were two cases of medical (stage II) and one 
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case of surgical (stage III) NEC after post-operative feeding. Post-guidelines, one infant 
developed medical NEC. Death was also a rare event. Two infants with a primary diagnosis of 
NEC died from respiratory failure in the pre-guideline period after resuming EN. Post-guidelines, 
two infants died within 24 hours of developing NEC; none have died since starting EN. One 
infant from each cohort was referred for intestinal transplantation. 
 Missing Data. In one pre-guideline infant, DB was never assessed. Total bilirubin was 
6.5 the first week of life; the infant was classified as “no IFALD.” For 10 infants, a total but not a 
direct bilirubin was assessed at the time of procedure (8 pre- and 2 post-guideline), but there were 
multiple subsequent DB measurements.   
DISCUSSION  
 We implemented a feeding intervention for surgical infants in the NICU at risk for IF. 
Compared to traditional trophic feeding volumes and advancement, the intervention resulted in 
higher volumes of initial post-operative feeding and shorter times to initiate and reach 50% of 
goal EN without unintended deleterious consequences, such as NEC, infection, or poor weight 
gain.  We also report decreased IFALD incidence and decreased peak DB.  Though the incidence 
of IFALD remains common in this high-risk population, the decrease in peak DB is clinically 
relevant - IF infants with higher DB are at greater risk for liver failure, liver transplantation, and 
mortality.2,14 The lack of statistical significance in reaching 100% EN may be a reflection of 
feeding difficulty seen as higher volumes are given, need for additional calories from PN, small 
sample size, and/or less stringent adherence to guidelines initially. 
 Despite education and evidence that higher initial volumes are tolerated in other high-risk 
infants, initial adherence to the guidelines was suboptimal.9,29,65,98 Adherence improved after 
implementing weekly nutrition rounds in the NICU, which facilitated communication, guideline 
adherence, and coordinating care. Other centers have also found that IR teams in general improve 
outcomes, as supported by a recent systematic review.33,70  
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 Confounding factors such as diagnosis, gestational age, method of feeding, infection, and 
lipid reduction strategies should be taken into consideration when interpreting these results. 
Though not statistically significant, the gestational age was higher in the post-guideline group. 
Thus far, there have been fewer cases of NEC as a primary diagnosis in the post-guideline cohort. 
We’ve seen an increase in infants with duodenal atresia and gastroschisis, similar to national 
trends, who required fewer and shorter resections.99 Since gestational age, percentage of residual 
bowel and NEC are risk factors for IFALD, the post-guideline infants may have been less prone 
to IFALD and IF. However, the decrease in IFALD severity is sustained in a sub-analysis of 
infants with NEC and SIP, and among the lower gestational ages. We also saw fewer culture-
proven infections in the post-guideline cohort, which may contribute to the severity of 
cholestasis. By chance, more infants were fed continuously initially in the post-guideline group, 
which may have impacted feeding tolerance and advancement. There was not a difference in the 
proportion of infants fed breast milk. The soy lipid restriction strategy for cholestasis did not 
change between periods; however, since starting weekly rounds, lipid restriction may be more 
consistently implemented, which may ultimately impact the severity of IFALD. There is 
conflicting evidence whether earlier and more aggressive lipid restriction strategies will further 
reduce IFALD risk.84,86  
 Since implementation of feeding guidelines, we have seen fewer days of PN use and a 
trend toward shorter lengths of stay. This may also be reflective of the difference in primary 
diagnoses, rather than a direct result of guideline use alone. None-the-less, the guidelines were 
relatively inexpensive to implement with only a modest increase in time commitment, and the 
potential cost-savings of reduced PN use and NICU hospitalization may ultimately have a 
significant impact on health care resource utilization. 
 Limitations of the study are the small sample size, heterogeneity of diagnoses and 
procedures, and single-center location. While these limitations are important, this pragmatic study 
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reflects “real world” experience with relatively rare surgical disorders. We plan to continue 
enrolling infants to increase the sample size, allowing for more complex statistical modeling, a 
better understanding of feeding tolerance among specific surgical subsets, and determination of 
sustainability over time. We also intend to evaluate the guidelines at another community-based 
children’s hospital to gain further insight about generalizability.  
 In conclusion, implementation of feeding guidelines for surgical infants was feasible, 
well tolerated, and resulted in shorter times to reach feeding goals.  We also report reduced 
IFALD incidence and peak direct bilirubin after implementation of the guidelines. Adherence to 





Abbreviations: IR, intestinal rehabilitation; QI, quality improvement; EN, enteral nutrition; 
NICU, neonatal intensive care unit; GI, gastrointestinal 
  
Table 3. Key Drivers and Interventions Used to Facilitate Implementation 
Key Drivers Interventions 
Multi-disciplinary Collaboration Formed IR team with key stakeholders 
Developed guidelines based on evidence and consensus 
Agreement by individual departments for implementation 
Education Nursing education through QI committee in-service and 
newsletter 
Provider education during faculty meetings and email 
distribution 
Accessibility of Guidelines Posted on nursing website 
Hard copies available bedside for rounds, posted in work 
rooms 
Daily reminders on rounds by dieticians 
Objective Measures Clear criteria for initiating and advancing EN 
Clear criteria for monitoring tolerance 
Data Sharing Pre-/post-guideline metrics shared quarterly with all 
providers  
Team meetings Monthly IR meetings to trouble shoot implementation and 
improve guidelines 
Weekly team rounds with NICU, Surgery, Nutrition & GI 
providers to facilitate real-time clinical decision making 
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Abbreviations: IQR, interquartile range; NEC, necrotizing enterocolitis; SIP, spontaneous 
intestinal perforation; PN, parenteral nutrition; DB, direct bilirubin    
aN=44 pre-guideline and N=20 post-guideline 
*P-values from Wilcoxon rank-sum and Fisher’s exact tests 
  
Table 4.  Demographics, Clinical, & Surgical Characteristics 
 Pre-guidelines    
N=57 
Post-guidelines 
  N=33 
P* 
Demographics    
Male (%) 33 (57) 17 (51) 0.661 
Ethnicity (% Hispanic)   1 (2)   2 (6) 0.552 
Race (%) 
  Black 
  White 
  Asian 




  2 (3) 




  1 (3) 
  1 (3) 
0.833 
Gestational age, weeks, median (IQR) 31.3 (27.2-36.9) 35.2 (31.4-37.1 ) 0.203 
Birth weight, g, median (IQR) 1523 (890-2680) 2170 (1325-2770) 0.293 
Birth weight z-score, median (IQR) -0.04 (-0.8 – 0.9) -0.25 (-0.95 – 0.29)  0.169 
Baseline Characteristics    
Diagnosis (%)  
  Atresia 
  Gastroschisis 
  Hirschsprungs 
  NEC 
  Other 
  SIP 
  Volvulus 
 
11 (19) 
  9 (16) 
  2 (4) 
21 (37) 
  3 (5) 
  9 (15) 
  2 (3) 
 
11 (33) 
  9 (27) 
  0 (0) 
  5 (15) 
  2 (6) 
  4 (12) 
  2 (6) 
0.200 
Pre-operative PN days, median (IQR)   5 (1-12)   2 (0-6) 0.042 
Baseline DB mg/dl, median (IQR) 0.5 (0.3 – 1.5) 0.4 (0.2-0.8) 0.105 
Surgical Characteristics    
Location of disease, >1 possible (%) 
  Duodenum 
  Jejunum 
  Ileum 
  Colon 
 














Initial procedures (%) 
  Peritoneal Drain 
  Resection/anastomosis 
  Resection/ostomy 
  Ostomy/no resection 
  Abdominal wall closure 
 




  9 (16) 
 
  3 (9) 
10 (30) 
10 (30) 
  1 (3) 
  9 (27) 
0.127 
Subsequent Procedures, >1 possible (%) 
  Resection/anastomosis  
  Resection/Ostomy 
  Abdominal wall closure 
  Ostomy reversal 
  
20 (35) 
  3 (5) 
  1 (2) 
24 (42) 
 
  3 (9) 
  1 (3) 
  0 (0) 






Total resection lengtha, median cm (IQR) 12 (6-22)   8 (0-22) 0.170 
Ileocecal valve present (%) 47 (82) 28 (85) 1.000 







































Abbreviations: IQR, interquartile range; EN, enteral nutrition; DB, direct bilirubin; IFALD, 
parenteral nutrition-associated liver disease; PN, parenteral nutrition; NEC, necrotizing 
enterocolitis  
adays from start of post-operative feeds; pre-guidelines: 50 infants reached 50%, 47 reached 
100%; post-guidelines: 32 infants reached 50% and 100%  
*P-values from Wilcoxon rank-sum and Fisher’s exact tests 
  
Table 5.  Nutrition Metrics, IFALD & Other Outcomes 
 Pre-guidelines 
  N=57 
Post-guidelines 
   N=33 
P * 
Nutrition Metrics  
1st post-operative feed, days 
median (IQR) 
13 (7-23)   8 (6-15) 0.048 
Type of post-operative feed (%) 
  Breast milk 
  Donor milk 
  Regular 
  Hydrolysate 
  Amino acid 
 
37 (65) 
  3 (5) 
  1 (2) 




  2 (6) 
  4 (12) 
  1 (3) 
  3 (9) 
0.156 
Initial feed volume, ml 
median (IQR) 
10 (6-14) 20 (10-20) <0.001 
Bolus feeds initially (%) 43 (77) 14 (42) 0.001 
50% EN,a days, median (IQR) 11 (5-21)   5 (3-12) 0.012 
100% EN,a days, median (IQR) 21 (8-36) 11 (6-20) 0.089 














  4 (12) 






Mucous fistula feeds (%)  8 (14) 2 (6) 0.315 
IFALD & Other Outcomes  
IFALD (%) 40 (70)   16 (48)   0.046 
Peak DB, mg/dl, median (IQR) 5.6 (0.8 – 9.5) 2.3 (1.5-5.0) 0.011 
DB >10mg/dl (%) 12 (21) 1 (3) 0.027 
Total PN, days, median (IQR) 52 (31-99) 22 (14-49) 0.012 
Home PN required (%) 9 (16) 1 (3) 0.084 
NEC after feeding (%)  3 (5) 1 (3) 1.000 
Culture-positive infection (%) 23 (40) 6 (18) 0.036 
Length of stay, days, median 
(IQR) 
82 (33-113) 52 (25-81) 0.077 
Discharge weight z-score, 
median (IQR) 




Figure 4. Feeding Guideline Decision Diagram.  
 
  
Abbreviations: PN, parenteral nutrition; EN, enteral nutrition; NG, nasogastric; NEC, 




Figure 5. Run chart of initial post-operative feeding volume among consecutive infants. The 
dashed gray line represents the baseline median. Once team meetings were implemented, a shift 
to higher initial volumes was seen (black line), with most infants starting enteral nutrition above 
the median of 10 ml/kg/day.  
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Figure 6. Run chart of days to reach 50% enteral nutrition (EN) after resuming feeding. The 
dashed gray line represents the baseline median.  Once team meetings were implemented, a shift 
was seen (black line), with most infants reaching 50% EN in <11 days. Gaps indicate infants who 






Figure 7. Run chart of days to reach 100% enteral nutrition (EN) after resuming feeding. The 
solid gray line represents the baseline median.  Once team meetings were implemented, a shift 
was seen, with most infants reaching 100% EN in <21 days. Gaps indicated infants who did not 









Figure 8. Run chart of peak direct bilirubin (DB) among sequential infants. The solid gray line 
represents the baseline median. After guideline implementation, a shift was seen; most infants 









CHAPTER 4. IMPROVED POST-OPERATIVE ENTERAL NUTRITION 
REDUCES THE RISK OF INTESTINAL FAILURE ASSOCIATED-LIVER 
DISEASE IN SURGICAL INFANTS 
ABSTRACT  
 
Background: Feeding practices vary for surgical infants at-risk for intestinal failure, and 
insufficient enteral nutrition (EN) is thought to contribute to intestinal failure-associated liver 
disease (IFALD). Our objective was to implement feeding guidelines to reduce the time to reach 
50% of EN and the incidence and severity of IFALD.  
Methods: Guidelines were implemented October 2013, and pre- (2007-2013) and post-guideline 
(2013-2016) cohorts were compared. Infants <6 months old undergoing intestinal surgery were 
included; those with pre-existing liver disease or surgery at outside facilities were excluded. Key 
modifications in the guidelines included higher initial EN volumes of 20 ml/kg/day and daily 
advancement if tolerated compared to pre-guideline practices. The primary outcomes were 
IFALD incidence (peak direct bilirubin [DB] >2mg/dl) and severity (DB>5 mg/dl). Other 
measures included initial EN volume, time to reach 50% and 100% goal calories from EN, and 
the incidence of necrotizing enterocolitis (NEC) after feeding.  
Results: There were 83 pre-guideline and 73 post-guideline infants. IFALD incidence decreased 
from 71 to 53% (P=0.03), and median peak DB decreased from 5.7 to 2.3 mg/dl (P=0.003). After 
adjusting for diagnosis and prematurity, the odds of developing moderate-to-severe IFALD was 
68% lower among infants in the post-guideline cohort (P=0.002). Comparing pre- and post-
guideline practices, the initial post-operative EN volume increased from 10 to 20 ml/kg/day 
(P=0.001), and time to reach 50% EN decreased from a median of 10 to 5 days (P=0.013). The 
incidence of NEC after initiating EN did not change (7 v 4, P=0.346). 
Conclusions: Implementation of feeding guidelines resulted in reduced time to reach 50% goal 
EN calories and reduced IFALD incidence and severity.  
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INTRODUCTION  
 The optimal strategy for feeding infants after intestinal procedures for disorders such as 
necrotizing enterocolitis (NEC), spontaneous intestinal perforation (SIP), gastroschisis, and 
atresia, is not well understood, resulting in variability amongst providers as well as feeding-
related risks.57,59 Such infants are at risk of complications of over-feeding, such as post-operative 
NEC, a highly morbid inflammatory process that can result in massive intestinal necrosis. 
Feeding intolerance from intestinal dysmotility can be difficult to distinguish from the early signs 
of NEC, resulting in understandable apprehension about feeding advancement. Infants may be 
kept on trophic feeding volumes for extended periods of time. Trophic EN volumes are meant to 
stimulate the intestine but provide minimal calories, and parenteral nutrition (PN) is therefore 
needed. Infants are also at risk of complications from under-feeding. Inadequate enteral nutrition 
and prolonged reliance upon PN increases the risk of central venous catheter-associated line 
infections and intestinal failure-associated liver disease (IFALD).11,19,22   
 IFALD typically manifests as cholestasis in the infant population, and is therefore 
defined as a direct bilirubin (DB) >2mg/dl that persists for >1 week in the setting of PN use and 
the absence of other etiologies of liver disease.8,9 IFALD remains common following intestinal 
surgery, with an incidence ranging from 25-60% depending on the center, and up to 70% in 
infants with NEC.10,13,58 For infants with intestinal failure, those requiring PN for >30-60 days, 
IFALD becomes a significant risk factor for chronic liver disease and the need for liver 
transplantation.14 The etiology of IFALD is multi-factorial, and is related to prematurity, 
prolonged PN exposure, lack of EN, and infection. As it is often unclear in the immediate post-
operative period which infants will meet criteria for intestinal failure, carefully optimizing EN in 
all at-risk infants is advisable.  
 In response to our previously reported high rate of IFALD and variable feeding practices, 
we created an intestinal rehabilitation team to guide post-operative feeding with the goal of 
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reducing the incidence of IFALD.71 Our feeding algorithm, implementation strategy, and interim 
success in reducing the time to reach feeding goals, overall PN exposure, and incidence and 
severity of IFALD were previously reported, comparing a baseline period 3 years prior to 
guideline implementation (57 infants) and 15 months after the implementation (33 infants).92  In 
this study we report our outcomes in an expanded cohort 6 years prior to and 2 ½ years after 
implementation of the feeding guidelines. 
 Our hypothesis was that adherence to feeding guidelines would shorten the time to reach 
enteral nutrition goals, which would in turn decrease PN exposure and therefore, decrease IFALD 
incidence and severity, the primary outcomes of interest.   
METHODS 
Study Design and Population 
 We performed a pre- and post-guideline implementation comparison. Retrospective data 
were collected on the pre-guideline cohort from January 2007-June 2013, and prospective data 
were collect on the post-guideline cohort from October 2013-June 2016. Approval and waiver of 
consent were obtained from the Institutional Review Board, as the feeding guidelines were 
implemented standard of care in the Neonatal Intensive Care Unit (NICU). Infants in the NICU 
with intestinal surgery prior to 6 months of age who survived to be fed enterally and required at 
least 7 days of PN were enrolled. Surgical procedures included enterotomy and enterostomy with 
and without resection, abdominal wall closure, and peritoneal drain. The principal diagnoses were 
NEC, SIP, intestinal atresia, gastroschisis, and volvulus. Infants were excluded if they had liver 
disease other than IFALD or if the primary surgical procedure was performed at outside facility. 
 Feeding Guidelines. Consensus- and evidence-based guidelines were developed by our 
Intestinal Rehabilitation team, which included representatives from neonatology, surgery, 
gastroenterology, nutrition, and nursing. These guidelines have been previously published.92 
Major changes in the guidelines, compared to previous usual care, included a higher initial post-
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operative EN volume and rate of feeding advancement. The initial recommended starting volume 
was 15-20 ml/kg/day. Exceptions included infants <1000 g who were not previously fed – such 
infants were fed according to another protocol of 1-2 ml every 6 hours for 5 days, and then the 
post-operative guidelines were followed.  The recommended advancement rate was 20 ml/kg/day 
every day if there were no signs or symptoms of intolerance. Signs of intolerance included 
increased ostomy or stool output, increased emesis, increased abdominal girth of >10%, or 
change in vital signs, such was increased apnea or bradycardia events. If signs of intolerance were 
present, EN was held at the current rate or decreased by 10-20%. If more worrisome signs such as 
blood in stools or clinical decompensation occurred, EN was discontinued. The individualized 
goal caloric requirement generally ranged from 110-130 kcal/kg/day and was determined by the 
dietician based on gestational age and growth. 
 Parenteral Nutrition. Only soy-based intravenous lipid was available at our center. PN 
lipid dosing remained the same in both study periods, and was generally increased to 3g/kg/day to 
meet caloric needs. Lipid restriction of 1mg/kg/day was employed once direct bilirubin was 
>2mg/dl.  
Data Collection and Metrics 
 Data were collected from the medical record and managed in an electronic database. Pre-
guideline infants were identified through surgical billing records. Post-guideline infants were 
identified at the time of surgery. Baseline Metrics. Sex, race, ethnicity, gestational age, birth 
weight, diagnosis, age at surgery, type of procedure, length and location of resection, residual 
small bowel, PN exposure prior to surgery, and baseline direct bilirubin at the time of surgery 
were recorded. 
 Post-operative Metrics. The first date, type, route, and volume of enteral nutrition were 
recorded. Weekly data included type, volume, and percent of calories of EN, PN lipid dose, 
weight and z-score, ostomy/stool output, and serum transaminases, total and direct bilirubin. The 
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volume of first post-operative feeding and rate of advancement were used to monitor adherence to 
guidelines, and potential deviations were clarified with the primary teams to determine lack of 
feeding advancement was due to EN intolerance vs. guideline deviation.  
 Outcomes. The primary outcomes were the incidence and severity of IFALD. The 
commonly utilized definition of IFALD in infants was used, defined as a direct bilirubin of 
2mg/dl that persisted for at least 1 week in the absence of other known liver disease.8 Mild 
IFALD was defined as direct bilirubin of 2-4.9mg/dl, moderate IFALD was defined as a peak 
direct bilirubin 5.0-9.9mg/dl, and severe IFALD was defined as a peak direct bilirubin 10 
mg/dl.2,78 Feeding outcomes included time (days) to reach 50% EN (>60 ml/kg/day with weaning 
PN) and 100% EN (>120 ml/kg/day EN with discontinuation of PN) from both the time of 
surgery and from the time of the first post-operative feeding. Other secondary outcomes included 
mortality, total number of PN days, culture-positive infection (blood, urine, or peritoneal fluid), 
development of NEC after post-operative feeding, length of stay, discharge weight z-score, and 
time to resolution of IFALD if it occurred.   
Statistical Analysis 
 The sample size estimate was based on our original IFLAD incidence of 70% among 
surgical infants. A sample size of 140 (70 per group) was estimated to be able to detect a 20% 
improvement in IFALD incidence with 80% power and a type 1 error rate of 5%.  With the 
current sample size, we had 90% power (alpha=0.05) to detect a 20% improvement in incidence 
of moderate-severe IFALD as well. 
 Given the relatively small sample sizes within the strata of the categorical variables and 
non-normal distribution of most continuous variables, we used Fischer exact tests to compare 
differences in categorical variables and non-parametric Wilcoxon rank-sum tests to compare the 
medians of continuous variables between the study periods. Non-normal continuous variables 
were log transformed and evaluated for normal distribution (using Shapiro-Wilk test)  
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 We used multiple logistic regression to examine the associations between IFALD (any 
severity, moderate-severe, and severe) and exposure to feeding guidelines, with adjustment for 
clinically and statistically significant patient characteristics (from bivariate analysis). We 
examined the potential confounding and modifying effects of gestational age, birth weight, sex, 
race, diagnosis, primary surgical procedure, and baseline direct bilirubin. A priori, diagnosis and 
gestational age were considered the most clinically relevant characteristics. Characteristics with a 
p-value of <0.1 were explored for use in the final model. Several variables were collinear and 
could not be used in the same model (type of surgery with diagnosis, age of surgery with 
diagnosis, baseline direct bilirubin with diagnosis, gestational age with birth weight). Diagnosis 
(NEC/SIP, gastroschisis, atresia, and other) and prematurity (gestational age <37 weeks) were the 
most clinically relevant, and were therefore used in the final model, along with race (White, 
Black, and Other) and sex. Model fit was evaluated with Akaike information criterion. All infants 
were included in the primary analysis. Missing data was assumed to be missing at random.   
 Kaplan-Meier survival curves were also used to compare times to reach events (50% EN, 
100% EN, and resolution of IFALD) between those in the pre- and post-guideline cohorts. Non-
overlapping confidence intervals were considered significant. Significance testing was also 
performed using the log-rank test for equality of survivor functions.  
 Statistical testing was two-sided, and P-values <0.05 were considered statistically 
significant. Analyses were performed with STATA (StataCorp. 2011. Stata Statistical Software: 
Release 12. College Station, TX: StataCorp LP). 
RESULTS 
 In the pre-guideline cohort, 83 infants were included, and 73 infants were included in the 
post-guideline cohort (Figure 9). 
 Baseline characteristics of both cohorts are described in Table 6. Age, sex, ethnicity/race, 
and gestational age were similar in both groups. The diagnoses of NEC, SIP, gastroschisis, 
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atresia, and other were also similar between cohorts.  The difference in surgical procedures 
between cohorts was due to the more frequent use of peritoneal drains in infants with NEC or SIP 
in the post-guideline cohort, compared to the more frequent ostomy use in these infants pre-
guidelines.  
Feeding Outcomes and Adherence to Guidelines  
 Similar to our previous interim results at 15 months post-implementation of guidelines, 
achievement of feeding goals was improved in the post-guideline cohort compared to the pre-
guideline cohort (Table 7). The time to initiation of EN post-operatively was decreased by a 
median of 5 days (P=0.017).  The volume of the initial post-operative feeding increased from a 
median of 10 to 20 ml/kg/day (P<0.001). In the post-guideline cohort, only two infants did not 
tolerate the first 24 hours of EN and had feeds held (one started at 20 ml/kg/day and one started at 
10 ml/kg/day). To account for differences in post-operative readiness to feed, longer nil per os 
(NPO) requirements for NEC, feeding tolerance once EN began and adherence to guidelines, time 
to reach 50% of goal EN was measured from both the time of surgery and time of initiation of 
post-operative EN. Time to reach 50% EN decreased by a median of 9 days from the time of 
surgery (P=0.005) and by a median of 5 days from the first post-operative feed (P=0.019). Time 
to reach 100% EN was still variable given the nature of critically ill premature infants with 
intestinal failure, and the difference in time was not statistically significant.  
 The odds of reaching 50% of EN within 7 days of starting EN were significantly higher 
in the post-guideline cohort (OR 6.5, P<0.001), even after adjusting for diagnosis and prematurity 
(Table 8). Time (in weeks) to reach 50% and 100% EN goals are also displayed using Kaplan-
Meier curves (Figure 10 & 11).  Improved time to reach feeding goals in the post-guideline 
cohort was again demonstrated. Time to reach feeding goals among infants with guideline 
deviations was intermediate between the other two groups, suggesting some improvement in 
reaching feeding goals even if guidelines were not strictly adhered to.   
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 Guideline adherence was overall good. Guideline deviations were defined by either using 
a lower than recommended initial post-operative feeding volume or lack of advancement in the 
absence of signs of intolerance. A total of 19 infants had at least one deviation. There were 14 
volume deviations (19%) and 12 advancement deviations (16%). Nearly half of the deviations 
(45%) occurred in the initial few months of the study prior to implementation of weekly multi-
disciplinary rounds. There were also intermittent deviations when new faculty less familiar with 
the guidelines were managing patient care. Deviations were most likely to occur in infants with a 
diagnosis of NEC or SIP (42%).  
 Breast milk was the type of EN used most frequently in both groups (Table 7). 
Continuous feeding was started more frequently in the post-guideline cohort. The mode of 
feeding (bolus vs. continuous) was not specified in the guidelines and this difference is a likely 
reflection of provider preference and increased number of patients with gastroschisis, who are 
more prone to vomiting. Re-feeding via mucous fistula was not common in either cohort. 
IFALD Incidence and Severity   
 When exploring all cases of IFALD, the cumulative incidence in the post-guideline 
cohort was lower compared to the pre-guideline cohort (53 vs. 71%, P=0.031); however, after 
adjusting for diagnosis and prematurity, this association was attenuated (odds ratio [OR] 0.50, 
P=0.076) (Table 8). The univariate analysis used to determine model selection for moderate-
severe IFALD is shown in Table 9. When exploring the more clinically relevant moderate-severe 
IFALD (DB 5mg/dl), the incidence was also less in the post-guideline group (29 v 56%, 
P=0.001), and the odds of developing IFALD remained statistically significant once adjusting for 
diagnosis and prematurity (OR 0.32, P=0.002).  
 Peak direct bilirubin and resolution of IFALD. The median peak direct bilirubin was 
lower in the post-guideline cohort (2.3 vs. 5.7 mg/dl, P=0.003). Among those infants who 
developed IFALD, resolution of IFALD by time of discharge was more likely to occur in the 
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post-guideline cohort, 64% vs. 25% (P<0.001). Time to resolution was also faster among those in 
the post-guideline cohort (P<0.001), displayed in Figure 12. The median discharge direct 
bilirubin was 1.0mg/dl (0.3-1.9) in the post-guideline group, compared to 2.4 mg/dl (0.6-4.8) in 
the pre-guideline cohort (P=0.001).  
 Moderate-to-severe IFALD was most commonly found in infants with NEC or SIP. 
Within the post-guideline cohort, 12 (48%) of infants with NEC/SIP developed moderate-to-
severe IFALD vs. 33 (73%) in pre-guideline cohort (P=0.041). Infants with these diagnoses were 
also prone to both feeding intolerance, as well as deviations from the guidelines (33%). The 
median peak direct bilirubin was 5.3 mg/dl (2.8-10.7) among those with guideline deviations 
(n=8) versus 4.7 mg/dl (1.7-6.0, P=0.008) among those without deviations (n=16). 
Other Outcomes  
 The adjusted odds of developing secondary outcomes for infants in the post-guideline 
cohort are also displayed in Table 8.   
 PN length use, length of stay, and discharge weight. The total days of PN use were 
decreased in the post-guideline cohort, 25 days (17-59) vs. 52 days (18-99, P=0.026). The 
number of infants who were discharged home on PN was 4 (6%) in the post-guideline cohort and 
12 (14%) in the pre-guideline cohort (P=0.070). Length of stay was shorter in post-guideline 
cohort, 52 days (26-84) vs. 80 days (33-124; P=0.027). Weight gain was similar in both cohorts, 
with median discharge weight z-score of -1.0 (-0.5--1.7) in the post-guideline cohort and -1.4 (-0.7-
-2.0) in the pre-guideline cohort (P=0.070). Weight z-scores of <-2.0 represent the bottom 5th 
percentile. Among the infants in the pre-guideline cohort, 19 (23%) had a discharge weight z-
score <-2.0 (range -2.1--5.1). In the post-guideline cohort, 8 (11%) infants had a discharge weight 
z-score <-2.0 (range -2.1- -4.7). 
 Post-operative necrotizing enterocolitis. Seven infants in the post-guideline cohort and 4 
infants in the pre-guideline cohort developed post-operative NEC (P=0.346). The original 
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diagnoses were SIP (4), NEC (3), atresia (2), gastroschisis (1), and meconium ileus (1). Medical 
NEC developed in 7 (63%), and 4 developed surgical NEC (36%). Three infants in the post-
guideline cohort developed NEC totalis and died. One infant had SIP, had only received a day of 
trophic elemental formula feeding and had remained in critical condition 3 weeks prior to the 
NEC event. The second infant had gastroschisis, had been tolerating full enteral feeds of 22 
kcal/oz. cow’s milk formula, and had been transferred out the NICU to the general floor for 
several days prior to sudden NEC event.  The third infant had an original diagnosis of NEC and 
had achieved full EN with donor breast milk fortified to 22 kcal/oz. for 3 days prior to NEC 
event. This infant had guideline departures for both lower than recommended initial volume (10 
ml/kg/day) and slower initial advancement.  
 Transplant referral and mortality. Both mortality (3 vs. 3; P=1.000) and need for 
intestinal transplant referral (1 vs. 1; P=1.000) were relatively rare and similar between cohorts.  
Enteral Nutrition as a Predictor of IFALD Sub-analysis  
 A sub-analysis was performed to evaluate the impact of timing of EN and IFALD 
irrespective of cohort assignment, to account for those infants fed more assertively prior to 
guideline development and those in the post-guideline cohort that had significant deviations from 
the guidelines. The odds of developing moderate-severe IFALD was explored based on time to 
reach 50% EN rather than participation in the guidelines (Table 10). Only infants with complete 
feeding data were included (N=128). The following were excluded: NEC (1), SIP (5), 
gastroschisis (5), atresia (5), Hirschsprungs (1), and volvulus (1). Exploration of the data showed 
an association between the rise in peak direct bilirubin and length of time to reach 50% EN, 
particularly within the first 21 days of surgery. None of the infants developed moderate-severe 
cholestasis if 50% EN was reached with 7 days of surgery, but only 14 (18%) infants were able to 
achieve feeds this quickly. Among the 44 infants (34%) who were able to achieve 50% EN within 
14 days, only 3 developed moderate cholestasis (all 3 had atresia). Reaching 50% EN within 21 
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days was feasible for 79 (56%) of the infants. The adjusted odds of developing moderate severe 
IFALD was reduced by 89% if 50% EN was reached within 21 days of surgery (P<0.001). With 
each additional week required to reach 50% EN, the odds of developing moderate-severe IFALD 
increased.  Figure 13 shows the distribution of peak DB by diagnosis, comparing those reaching 
50% EN within 21 days to those infants that took longer.  
 In a separate analysis, how quickly EN was achieved once feeding began (regardless of 
time to start EN post-operatively) was also evaluated. The adjusted odds of developing moderate-
severe IFALD was decreased by 87% if 50% EN was reached within 7 days of initiating EN 
(P<0.001); however 12 of 64 (19%) of infants reaching 50% EN within 7 days still developed 
moderate-severe cholestasis. Those diagnoses included NEC (4), atresia (4), SIP (3), and volvulus 
(1). These results suggest there was benefit in quickly advancing EN to 50% once post-operative 
feeding began, but a delay in starting feeds post-operatively can still result in moderate-severe 
IFALD.  
Missing Data  
 Baseline direct bilirubin was missing from 17 infants (11%); 11 were in the pre-guideline 
cohort and 6 were in the post-guideline cohort. As the baseline direct bilirubin was collinear the 
diagnosis, this variable was not included in the final analysis and therefore did not affect the 
analysis. Missing feeding data from the pre-guideline cohort included 4 infants (5%) without the 
date of post-operative EN initiation, 30 infants (36%) without the first post-operative EN volume, 
26 infants (31%) without the known date to reach 50% EN. In the post-guideline cohort, 3 infants 
were not yet discharged, so length of stay and discharge growth parameters were missing. 
Discharge growth parameters were missing from 7 (8%) in the pre-guideline cohort.  
DISCUSSION  
 IFALD remains a common complication in infants following intestinal surgery. The 
diagnosis of IFALD includes a wide range of direct bilirubin values, and the clinical significance 
 53 
of IFALD varies by cholestasis severity. Infants with more severe cholestasis are at higher risk of 
chronic liver disease, and ultimately at a higher risk of needing liver transplantation, particularly 
if PN cannot be discontinued.14,81 Optimizing EN reduces the risk of IFALD, and feeding 
guidelines offer a systematic approach to feeding by reducing inter-provider variability. After 
implementing post-operative feeding guidelines in our NICU, we have seen faster achievement of 
enteral feeding goals and reduced IFALD severity.  
 While the overall risk of IFALD decreased with the use of the guidelines, 50% of infants 
still developed at least mild IFALD. The odds of developing at least moderately severe IFALD, a 
more clinically germane complication, were significantly reduced in by 68% the post-guideline 
cohort, and this difference remained significant with adjustment for diagnosis and prematurity. 
Severe cholestasis was rare in the post-guideline cohort. Infants in the post-guideline cohort who 
did develop IFALD were more likely to have resolution of cholestasis prior to discharge and 
resolution occurred more quickly compared to the pre-guideline cohort.  
 Feeding guidelines are emerging in NICUs in effort to balance the benefits of EN with 
the risk of NEC in high-risk infant populations.29,64 Minimal EN regimens (trophic feeding) are 
often used in high risk patients, however broad ranges in trophic volumes (5-20 ml/kg/day) make 
studies of feeding practices difficult to compare to determine the ideal volume and duration of 
minimal EN.66 Early feeding likely has advantages. A study of premature infants showed early 
feeding (within 48 hours of birth) improved feeding tolerance and decreased exposure to PN, 
without an increase in NEC.65 In infants with very low birth weight or congenital heart disease, 
both at higher risk for NEC, feeding protocols resulted in faster achievement of EN goals without 
increased NEC.63,68,100 The American Society for Parenteral & Enteral Nutrition (ASPEN) found 
sufficient evidence to support early initiation of EN and advancing by 30 ml/kg/day in non-
surgical infants at-risk for NEC.69 For surgical infants, a recent systematic review found improved 
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outcomes in general when care was provided by multi-disciplinary intestinal rehabilitation team 
focused on nutrition support.70 
 The ideal volume of EN needed to offer protection from IFALD in surgical infants is not 
known. In our pre-guideline cohort, infants were routinely kept on prolonged trophic volumes of 
EN (<20 ml/kg/day), and the incidence of IFALD was 70%. The incidence of moderate-to-severe 
cholestasis was 56%. In devising the guidelines, we hypothesized that 50% EN would be more 
protective against IFALD than trophic feeds. This goal volume was based on anticipated clinical 
tolerance, ability to wean PN calories at this volume, and our previous data suggesting protection 
from IFALD among infants fed more quickly. While the study does encompass a heterogeneous 
group of infants, we believe the general principles for initiation and early advancement of EN are 
applicable to most infants with intestinal surgery. Nearly all infants tolerated an initial post-
operative feeding volume of 20 ml/kg/day and were able to tolerate daily advancement of 20 
ml/kg/day up to 60-80 ml/kg/day (50% of goal EN volume), even among infants <1000g. 
However, infants who were <1000 g and not previously fed were kept on trophic feeding volumes 
for the first 5 days in accordance with our very low birth weight feeding protocol.  How quickly 
EN could be advanced past 50% EN was highly individualized and affected by motility, 
malabsorption and other co-morbidities that affect critically ill infants (interruptions in EN for 
other procedures, possible infection, changes in respiratory status, etc.).   
 Achieving 50% of goal calories from EN within 14-21 days of surgery appeared to be 
protective against moderate-severe IFALD, regardless of diagnosis of NEC, SIP, gastroschisis, or 
atresia. The infants who were able to quickly achieve 50% of EN had lower odds of developing 
moderate-severe IFALD even if the time to reach 100% EN was still prolonged. Part of the 
challenge of achieving 50% of EN more quickly is being able to start post-operative EN in a 
timely manner.  
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 The ideal time to begin feeding post-operatively is also unclear. In the post-guideline 
cohort, the time to initiate post-operative EN was shorter. This change is likely a combination of 
purposeful earlier introduction of feeding based on weekly discussions and increased comfort 
with earlier feeding among providers, as well as fewer infants in the cohort with a diagnosis of 
NEC. Infants with NEC rarely started EN prior to 14 post-operative days, and often had slower 
advancement, both due to feeding intolerance and due to provider reluctance to advance PN. 
Readiness to feed is often based on clinical signs such as abdominal distention and stool or 
ostomy output. More informative criteria for determining readiness to feed are needed to guide 
clinical care.   
 The feeding guidelines were generally well tolerated. The incidence of NEC in the post-
operative period was monitored as a potential adverse event of enteral feeding. NEC occurs in 2-
7% of NICU admissions.7,101 NEC most commonly occurs in preterm infants and recurs in 10% of 
infants.7,102 NEC has also been reported in 10-20% of infants with gastroschisis.103 Careful 
monitoring with all feeding advancement is therefore necessary. While not statistically different 
from the pre-guideline cohort or outside the incidence reported at other centers, 7 cases of NEC 
occurred after post-operative feeding in the post-guideline cohort. In one of the deaths following 
NEC, the infant was not being fed. In the other two cases, the infants had already achieved 100% 
EN volume and EN had been fortified to 22 kcal/oz. While our guidelines do not specifically give 
recommendations for fortification, it is generally our practice not to fortify above 24 kcal/oz. 
unless significant growth restriction persists. Strategies for fortification in infants at risk of NEC 
are currently debated in the literature without clear best practices.104  
 Other factors may have also affected severity of IFALD in our study, including the 
reduced infection rate in the post-guideline cohort. The difference in infection (positive culture in 
blood, urine, or peritoneal fluid) between cohorts is likely multi-factorial. Attention to central line 
care has improved, reducing the risk of infection. Improved EN promotes intestinal mucosal 
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barrier function, thereby reducing intestinal bacterial translocation and reducing the risk of 
infection.31,105 Faster achievement of EN also allows for sooner discontinuation of PN and the 
central catheter, reducing risk. A potential modifying effect on IFALD severity cannot be entirely 
excluded, as infection can also cause elevation of bilirubin.  
 The limitations of the study include a relatively small sample size to adjust for potential 
confounders, and data are from a single center. Due to chance, there was heterogeneity in 
diagnoses between cohorts, though not statistically significant. Gestational age and birth weight 
were very similar between cohorts. Our baseline IFALD risk was higher than the incidence 
reported at other centers. None-the-less, we have seen continued improvement in outcomes once 
guideline adherence was achieved.  Further studies are in progress with another site to test the 
generalizability of the guidelines, and will allow for further risk stratification by diagnosis and 
other risk factors. As we collect more data, more refined strategies for EN advancement are also 
expected to emerge.  
 In conclusion, our post-operative feeding guidelines have been well tolerated. Guideline 
use has resulted in shorter times to initiate post-operative EN and reach 50% of goal EN. With 
improved EN, we have seen a modest reduction overall IFALD incidence and a significant 




Table 6.  Demographic, Baseline, & Surgical Characteristics 
 Pre-Guidelines 
   N=83 
Post-Guidelines 
   N=73 
P * 
Demographics    
Male (%) 51 (61) 38 (52) 0.260 
Ethnicity (% Hispanic) 4 (5) 4 (5) 1.000 
Race (%) 
  Black 
  White 








 4  (6) 
0.498 
Gestational age, weeks, median (IQR) 33.0 (27.1-37.0) 34.4 (27.7-37.0) 0.582 
Birth weight, g, median (IQR) 1610 (920-2575) 2065 (910-2700) 0.558 
Birth weight z-score, median (IQR) -0.1 (-0.8-0.9) -0.2 (-0.9-0.3) 0.185 
Baseline Characteristics    
Primary Diagnosis (%)  
  Atresia 
  Gastroschisis 
  NEC 
  SIP 
  Volvulus 





15 (18)  
  2 (2) 






  3 (4) 
  8 (11) 
0.135 
Age of first feed, days, median (IQR)   8 (3-18)   9 (3-14) 0.701 
Pre-operative PN days, median (IQR)   5 (1-12)   4 (1-7) 0.158 
Baseline DB mg/dl, median (IQR) 0.5 (0.3-1.5) 0.4 (0.2-0.7) 0.058 
Surgical Characteristics 5 (1-12) 4 (1-7) 0.158 
Age at surgery, days, median (IQR) 7 (3-16) 6 (3-9) 0.170 
Initial procedure (%) 
  Peritoneal Drain 
  Resection/anastomosis 
  Resection/ostomy 
  Ostomy/no resection 
  Abdominal wall closure 
 









  3 (4) 
20 (27) 
0.001 
Subsequent Procedures (%) 
  Resection/anastomosis  
  Resection/Ostomy 
  Abdominal wall closure 
  Ostomy reversal 
(>1 choice possible) 
 
26 (31) 
  6 (7) 
  3 (4) 
34 (41) 
 
  6 (8) 
  6 (8) 




  1.000 
  0.623 
  0.002 
Total resection lengtha, median cm 
(IQR) 
12 (5-17) 10 (6-25) 0.941 
Residual bowela, percent (IQR) 92 (68-97) 89 (79-94) 0.896 
Ileocecal valve present (%) 65 (78) 61 (83) 0.350 
Colon preserved (%) 74 (89) 68 (93) 0.335 
Abbreviations: IQR, interquartile range; PN, parenteral nutrition; DB, direct bilirubin 
aIf resection occurred (N=67 historical and N=33 guidelines) 




Table 7.  Feeding Metrics & Outcomes 
 Pre-Guidelines 
   N=83 
Post-Guidelines 
   N=73 
P * 
1st post-operative feed, days 
median (IQR) 
13 (7-25) 9 (6-15) 0.017 
Type of post-operative feed (%) 
  Breast milk 
  Donor milk 
  Regular 
  Hydrolysate 
  Amino acid 
 
51 (65) 
  3 (4) 
  4 (5)   




  5 (7) 
  6 (8) 
  1 (1)   
  4 (6) 
0.024 
 
Initial feed volume, ml/kg/day 
median (IQR) 
10 (8-14) 20 (10-20) <0.001 
Bolus feeds initially (%) 50 (68) 36 (49) 0.028 
50% EN,a days, median (IQR) 10 (4-20) 5 (3-12) 0.019 
100% EN,a days, median (IQR) 19 (6-32) 11 (6-21) 0.115 





















Mucous fistula feeds (%) 8 (11) 4 (6) 0.370 
Abbreviations: IFALD, intestinal failure-associated liver disease, IQR, interquartile range; DB, direct 
bilirubin PN, parenteral nutrition; NEC, necrotizing enterocolitis, SB, small bowel 
aDays to reach feeding goals from time of first post-operative feed 
















      
IFALD 
(DB>2mg/dl) 
 59 (71) 39 (53) 0.47 (0.24-
0.90) 




46 (56) 21 (29) 0.30 (0.15-
0.58) 
<0.001 0.32 (0.15-0.67) 0.002 
Severe IFALD 
(DB>10mg/dl) 
16 (20)   6 (8) 0.37 (0.14-
0.42) 
0.050 0.36 (0.12-1.05) 0.062 
Secondary 
Outcomes 
      
50% ENa <7 
days 





Resolved IFALD 15 (25) 25 (64) 5.24 (2.17-
12.6) 
<0.001 6.96 (2.55-19.0) <0.001 
Post-op NEC   4 (5)   7 (10) 2.0 (0.58-
7.46) 
0.254 2.10 (0.56-7.91) 0.270 
Positive Culture 34 (41) 12 (16) 0.28 (0.13-
0.60) 
0.001 0.29 (0.13-0.67) 0.004 
Mortality    3 (4)  3 (4) 1.1 (0.22-
5.84) 
0.873 2.10 (0.32-14.0) 0.441 
Abbreviations: OR, odds ratio, CI confidence interval, IFALD, intestinal failure-associated liver disease, 
DB, direct bilirubin, EN, enteral nutrition, NEC, necrotizing enterocolitis, PN, parenteral nutrition 
*Adjusted for diagnosis (necrotizing enterocolitis/spontaneous intestinal perforation, gastroschisis, atresia, 
and other), prematurity (gestational age <37 weeks), sex, and race (Black, White, Other) 
aTime to reach 50% EN from initial post-operative EN. Similar results seen to time to reach 50% 




Abbreviations: IFALD, intestinal failure-associated liver disease, OR, odds ratio, CI confidence interval, 
NEC, necrotizing enterocolitis, SIP, spontaneous intestinal perforation, DB, direct bilirubin, PN, parenteral 
nutrition 
*Adjusted for diagnosis (necrotizing enterocolitis/spontaneous intestinal perforation, gastroschisis, atresia, 




Table 9. Univariate and multivariate analysis of odds of developing moderate IFALD by 
risk factors 
Variable Unadjusted OR (CI) P  Adjusted OR* 
(CI) 
P   
Enrolled in guidelines 0.32 (0.16-0.62)   0.001 0.32 (0.15-0.67) 0.003 
Diagnosis  <0.001  0.012 
     NEC/SIP  Ref  Ref  
     Atresia 0.18 (0.07-0.45)  0.29 (0.10-0.85)  
     Gastroschisis 0.15 (0.06-0.41)  0.20 (0.07-0.58)  
     Other 0.30 (0.11-0.85)  0.50 (0.15-1.63)  
Prematurity 3.52 (1.62-7.64) 0.001 2.18 (0.85-5.53) 0.090 
Sex (male) 0.80 (0.42-1.53) 0.505 0.71 (0.33-1.51) 0.374 
Race  0.348  0.465 
      Black Ref  Ref  
      White 0.51 (0.18-1.46)  0.88 (0.41-1.89)  
      Other 0.39 (0.07-2.23)  0.40 (0.09-1.71)  
Gestational age (log) 0.004 (0.0005-0.037) <0.001   
Birth weight (log) 0.20 (0.10-0.37) <0.001   
Age at surgery (log) 0.21 (1.10-1.93)   0.009   
Baseline DB (log) 4.44 (1.99-9.90) <0.001   
PN prior to surgery (log) 1.65 (1.13-2.41)   0.009   
Positive culture 7.66 (3.46-16.92) <0.001   
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Table 10. Univariate and multivariate analysis of odds of developing moderate IFALD 







OR (CI) P   Adjusted 
OR (CI) 
P  
50% EN ≤14 
days 





50% EN ≤21 
days 





Abbreviations: IFALD, intestinal failure-associated liver disease; EN, enteral nutrition 
*Adjusted for diagnosis (NEC/SIP, Gastroschisis, Atresia, and Other), prematurity (gestational age <37 
weeks), sex, and race (Black, White, Other) 


























Eligibility Screening: N=91 
Post-Guidelines 
Eligibility Screening: N=85 
Excluded: N=8 
-1 other liver disease 
-3 surgery at other center 
-4 PN < 7 days 
Excluded: N=12 
-2 other liver disease 
-3 surgery at other center 
-3 PN < 7 days 
-1 never fed 
-3 died prior to feeding 
 
Enrolled Participants: N=83 
 
 
Enrolled Participants: N=73 
  
Figure 1. Diagram of study design, enrollment, and participation  
Per Protocol: N=54 Deviations: N=19 
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Figure 12. The time to resolution of intestinal failure-associated liver disease (IFALD) from the 






Figure 13. The peak direct bilirubin is shown by diagnosis, comparing infants able to reach 50% 























Chapter 5: Conclusions 
 
 Feeding infants after intestinal surgery is challenging, and such infants are at risk of 
developing intestinal failure and intestinal failure-associated liver disease (IFALD) as 
complications. To better understand the impact of enteral nutrition (EN) on the risk of IFALD 
among infants who have had intestinal surgery, we have conducted three separate studies. 
 In our baseline assessment of post-operative feeding practices and incidence of IFALD in 
the preceding five years, we found an unexpectedly high incidence of IFALD (60-90%), 
including a high incidence of moderate-severe IFALD with a median peak direct bilirubin of 
7.5mg/dl. We also found considerable variability in feeding practices and prolonged use of 
trophic feeding with EN volumes <20 ml/kg/day. With that data, we then formed a multi-
disciplinary neonatal intestinal rehabilitation team and created post-operative feeding guidelines 
for initiating and advancing EN and managing parenteral nutrition.  
 In our second study, we evaluated the implementation process of the feeding guidelines, 
adherence to guidelines, and the interim impact of the guidelines upon reducing the time to reach 
EN goals, and the incidence and severity of IFALD, compared to a pre-guideline cohort.  In the 
first few months, there was suboptimal adherence to the guidelines, but after implementing 
weekly multi-disciplinary rounds, adherence improved. In real time, we saw shifts to higher 
initial EN volumes, reduced time to reach 50% of goal enteral nutrition, and a reduction in both 
IFALD incidence and peak direct bilirubin. During this time period, we also saw fewer cases of 
NEC, which have the highest risk of IFALD. However, even among infants with NEC, the 
severity of peak direct bilirubin decreased. We did not identify any unintended deleterious 
consequences from implementation of the guidelines, and the incidence of post-operative NEC 
was similar between cohorts.  
 Two and a half years after implementation of the guidelines, we reached our target 
sample size to evaluate whether being enrolled in the feeding guidelines reduced the odds of 
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developing IFALD. We found that IFALD remained fairly common, but the severity of IFALD 
was significantly improved in infants in the post-guideline cohort. The overall incidence of 
IFALD decreased from 70% to 53% (P=0.03). We found a significant reduction in the adjusted 
odds of developing moderate-to-severe IFALD (OR 0.32, P=0.002) among infants fed via the 
guidelines. Since infants with higher peak direct bilirubin are at higher risk of having chronic 
liver disease, a reduction in moderate-severe IFALD is of clinical importance. We also found that 
infants in the post-guideline cohort had a shorter length of PN use, shorter hospital length of stay, 
fewer infections with positive culture, and were more likely to have resolution of IFALD prior to 
discharge if IFALD did occur.  
 The higher initial feeding volume of 20 ml/kg/day recommend in the guidelines was well 
tolerated. Infants who were adherent to the guidelines reached 50% EN in the shortest amount of 
time. We found that even if full EN could not be reached for a prolonged period of time, reaching 
50% of goal EN within 2-3 weeks of surgery still offered protection against moderate-severe 
IFALD.  
 While we have made significant progress in improving enteral feeding in surgical infants, 
barriers still remain for feeding the sickest of the infants, who are also most at risk of IFALD. We 
plan to continue monitoring the impact of our feeding guidelines on surgical infants to further 
define optimal feeding based on prematurity and diagnosis. Collaboration with a second site is 
already underway, which will evaluate the generalizability of the guidelines, and will provide a 
larger sample size to allow for further risk stratification.  One major barrier to feeding has been 
predicting readiness to feed. Identifying which infants are ready to initiate EN and which require 
longer withholding of EN is based on non-specific assessment of vital signs, physical 
examination, and gastrointestinal output. Clinically available testing to assess readiness to feed is 
not yet available.  Our future work will also evaluate potential serum biomarkers of several 
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mechanisms of intestinal injury, including enterocyte damage, barrier dysfunction, and 
inflammation, which may provide clinically useful adjunct testing to predict readiness to feed.  
 Taken together, these studies suggest that EN plays an important role in mitigating the 
risk of IFALD. Feeding guideline implementation was feasible and well tolerated. We have seen 
improved outcomes since implementing the guidelines, and we will continue with our efforts to 
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